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Abstract 
Translation initiation is a critical early step in the replication cycle of the positive-sense, single-stranded RNA 
genome of noroviruses, a major cause of gastroenteritis in humans. Norovirus RNA, which has neither a 5´ m7G 
cap nor an internal ribosome entry site (IRES), adopts an unusual mechanism to initiate protein synthesis that 
relies on interactions between the VPg protein covalently attached to the 5´-end of the viral RNA and eukaryotic 
initiation factors (eIFs) in the host cell.  
For murine norovirus (MNV) we previously showed that VPg binds to the middle fragment of eIF4G (4GM; 
residues 652-1132). Here we have used pull-down assays, fluorescence anisotropy, and isothermal titration 
calorimetry (ITC) to demonstrate that a stretch of ~20 amino acids at the C terminus of MNV VPg mediates 
direct and specific binding to the HEAT-1 domain within the 4GM fragment of eIF4G. Our analysis further reveals 
that the MNV C-terminus binds to eIF4G HEAT-1 via a motif that is conserved in all known noroviruses. Fine 
mutagenic mapping suggests that the MNV VPg C terminus may interact with eIF4G in a helical conformation. 
NMR spectroscopy was used to define the VPg binding site on eIF4G HEAT-1, which was confirmed by 
mutagenesis and binding assays. We have found that this site is non-overlapping with the binding site for eIF4A 
on eIF4G HEAT-1 by demonstrating that norovirus VPg can form ternary VPg-eIF4G-eIF4A complexes. The 
functional significance of the VPg-eIF4G interaction was shown by the ability of fusion proteins containing the C-
terminal peptide of MNV VPg to inhibit translation of norovirus RNA but not cap- or IRES-dependent translation. 
These observations define important structural details of a functional interaction between norovirus VPg and 
eIF4G and reveal a binding interface that might be exploited as a target for antiviral therapy.  
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Introduction 
The Caliciviridae family of positive-sense, single-strand 
RNA viruses includes 5 genera that infect a variety of 
animals: Norovirus, Lagovirus, Nebovirus, Sapovirus and 
Vesivirus. Of these, the noroviruses constitute the greatest 
threat to human health. They cause around 18% of all 
cases of acute gastroenteritis worldwide and an estimated 
200,000 deaths a year in children under 5 in developing 
nations [1,2].  The Norovirus genus contains 6 genogroups 
(GI-GVI), three of which infect humans (GI, GII and GIV). 
The murine noroviruses (MNV) of the GV genogroup only 
infect rodents and have been studied extensively as a 
convenient model for human norovirus infections [3-6].  
A critical step in calicivirus replication following delivery of 
the viral RNA to the cytoplasm of infected cells is the 
initiation of translation. As obligate intracellular parasites, 
viruses need to gain access to the protein synthesis 
machinery and, in common with many other viruses, 
caliciviruses do this by partially circumventing the host 
mechanisms of translation initiation [7]. The initiation of 
protein synthesis is a complex and highly regulated 
process by which the 43 S ribosomal initiation complex is 
first recruited to an mRNA molecule and then directed to 
the AUG start codon [8]. In eukaryotes this process 
involves a multitude of protein initiation factors along with 
initiator tRNA.  
In the normal or canonical mechanism of ribosomal 
recruitment an important early step is the binding of the 
heterotrimeric eukaryotic initiation factor 4F (eIF4F) to the 
m7G cap at the 5´end of the mRNA. eIF4F mediates 
binding of the mRNA to the 43 S ribosomal initiation 
complex via its interaction with eIF3 and, in concert with a 
number of other initiation factors, promotes scanning of the 
mRNA until the initiation complex locates the AUG start 
codon [8,9]. At this point ribosomal assembly is completed 
and protein synthesis commences. eIF4F consists of a 
large, multi-domain ‘platform’ protein, eIF4G, which has 
independent sites for recruitment of eIF4E, the cap-binding 
protein, and eIF4A, an ATP-dependent RNA helicase that 
melts RNA secondary structure to facilitate ribosomal 
scanning (Fig 1A). eIF4G also serves as a platform for 
other proteins such as the polyA-binding protein 
(PABP), which augments the efficiency of translation 
initiation, and the MAP kinase-interacting kinases 1 
and 2, which are involved in regulation (reviewed in 
[9]). In humans there are two closely-related 
paralogs of eIF4G (I and II) which share 46% 
sequence identity [10]; there are also a number of 
alternatively spliced isoforms for each paralog but 
the differentiation of their functions in translation has 
yet to be fully determined [11].  DAP5 (Death-
associated protein 5; also known as p97, NAT-1 and 
eIF4G2) is another eIF4G paralog [12]. It is missing 
the N-terminal portions of eIF4GI and eIF4GII which 
contain the motifs that bind PABP and eIF4E but it 
otherwise similar in domain structure to the C-
terminal two-thirds of these proteins (Fig 1A), 
sharing 39% and 43% amino acid sequence identity 
respectively. 
The adoption of non-canonical mechanisms of 
ribosomal recruitment is used by some RNA viruses 
to gain an advantage over host cell mRNA in 
competing for ribosome recruitment. A common 
strategy is the use of an internal ribosome entry site 
(IRES), a large RNA structure within the 5
´untranslated region (5´UTR) of the viral genome, 
which can mediate ribosome binding independently 
of a 5´cap and which typically has a reduced 
dependency on eIFs for translation initiation [13]. 
Viruses in possession of an IRES can therefore gain 
a competitive advantage by disabling redundant eIFs 
that are critical for cap-dependent translation 
initiation [7,14-17]. Some of the best-studied 
examples of this strategy are to be found among the 
picornaviruses (e.g. poliovirus (PV), human 
rhinovirus (HRV), and foot-and-mouth disease virus 
(FMDV)) [18-20]. Their RNA genomes lack a 5´cap 
and encode proteases (PV 2Apro, HRV 2Apro, FMDV 
Lpro) that can specifically cleave eIF4G to separate 
the binding sites for eIF4E and eIF4A [21]. This 
disables cap-dependent translation initiation, leading 
to shut-off of host cell protein synthesis, but does not 
impair IRES-dependent translation initiation from the 
viral genome, which only requires the large C-
terminal fragment of eIF4G retaining the binding site 
for eIF4A [9]. Consistent with its inability to bind the 
cap-binding protein eIF4E, DAP5 has been reported 
to preferentially support IRES-dependent translation 
initiation [22].   
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Figure 1: MNV VPg interacts with eIF4GI via its HEAT-1 domain. (A) Schematic 
representation of eIF4GI (NCBI accession AAM69365.1), one of two eIF4G 
paralogues expressed in humans, and the paralog DAP5 (NCBI accession 
NP_001036024.3). Positions of domains that interact with other proteins of the 
translation initiation machinery are indicated, as are the cleavage sites of FMDV L 
protease and Rhinovirus 2A protease. The principal eIF4G fragments that were sub-
cloned for use in this study are also indicated. (B) SDS PAGE -analysis of glutathione 
affinity pull-down assays that were performed to map the locus of MNV VPg binding. 
GST-fusions of various eIF4GI fragments (shown in panel A) were used as bait and 
His-tagged-MNV VPg(1-124) as prey. Left panel: protein mixtures applied to the 
glutathione-sepharose 4B beads (lanes 1–6). Right panel: proteins eluted with 10 mM 
glutathione (lanes 7–12). (C) SDS PAGE analysis of cobalt affinity pull-down assays 
performed to confirm the eIF4G HEAT-1 domain as the locus of MNV VPg binding. 
His-tagged-MNV VPg 1-124 or His-tagged-FCV VPg 1-111 as bait proteins and GST-
fusions of various eIF4GI fragments were used as prey. Left panel: protein mixtures 
applied to the cobalt resin (Lanes 1–6). Right panel: proteins eluted with 250 mM 
imidazole (lanes 7–12).
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Although picornaviruses and caliciviruses 
share many similarities in their genome 
structures and replication cycles, 
caliciviruses have acquired completely 
different mechanism for translation initiation. 
They have no IRES – indeed their 5´UTRs 
are very small, in some cases as short as 4 
nucleotides (nt) [5,23] – but instead rely on a 
small protein called VPg (Virus Protein, 
genome-linked) of ~110-140 amino acids 
that is covalently linked to the 5´end of the 
viral genome for translation initiation. 
Picornaviruses are also known to have a 
VPg attached to the 5´ends of their RNA 
genomes but the picornaviral protein, which 
is typically only around 22 amino acids and 
structurally unrelated to its caliciviral 
equivalent, is rapidly removed following cell 
entry [24] and plays no part in translation 
[25,26]. In contrast, proteolytic digestion of 
caliciviral VPg in vitro has long been known 
to render its RNA non-infectious and to 
prevent translation in vitro [27-30]. The 
observation that infectivity of caliciviral RNA 
can be restored by covalent attachment of a 
5´ m7G cap suggests that VPg serves as a 
proteinaceous cap analogue [30,31]. 
However, the particulars of the mechanism 
by which VPg performs this role have yet to 
be fully elucidated.  
Picornavirus VPg peptides appear to be 
largely unstructured in aqueous buffer [32], 
but recent work of the solution structures of 
caliciviral VPg proteins from three different 
genera has revealed that they all contain a 
helical core flanked by unstructured N and C 
termini. The feline calicivirus (FCV, a 
vesivirus) and porcine sapovirus (PSaV) 
VPg cores consist of very similar 3 helix 
bundles, while the core of MNV VPg is 
somewhat truncated and contains just the 
first two helices found in the other two 
proteins [33,34].  
These structural similarities belie the fact that, despite 
being critical for translation initiation, VPg proteins from 
different caliciviruses appear to perform this function in 
different ways. One of the earliest studies found that the 
VPg of noroviruses interact with eIF3 but the mechanistic 
implications of this finding remain unclear [35,36]. Direct 
interactions with eIF4E have been reported for FCV VPg 
and MNV VPg [37] but, while this interaction appears to be 
crucial for FCV, its significance for MNV is more 
questionable. For example, disruption of the eIF4E-eIF4G 
interface by the translational regulator 4E-BP1 inhibits FCV 
translation, but has no effect on MNV translation [27]. 
Moreover, FCV translation is abrogated if FMDV Lpro is 
allowed to digest eIF4G, thereby separating its eIF4E and 
eIF4A binding domains, but MNV translation is unaffected 
by this proteolytic cleavage. These findings reinforce the 
idea that FCV VPg probably operates as a functional 
analogue of the m7G cap, by interacting directly with eIF4E, 
whereas MNV relies on a distinct mode of interaction with 
eIF4F (see below). More recent work suggests that PSaV 
VPg may direct translation initiation by a mechanism 
similar to FCV VPg since it also binds directly to eIF4E 
[38]; moreover, PSaV translation in vitro also exhibits the 
same sensitivity to inhibition by 4E-BP1 and Lpro digestion 
of eIF4G.  
The translation initiation directed by MNV VPg may not be 
completely independent of eIF4E in view of a recent study 
showing that modulation of the MAPK pathway to stimulate 
phosphorylation of eIF4E during MNV1 infection helps to 
promote virus replication [17]. Nevertheless it is clear that 
the interaction of MNV VPg with eIF4E is not its primary 
mode of engagement with the translational machinery. 
Recent work revealed that MNV VPg is instead capable of 
forming a specific interaction with eIF4G [39]. The 
interaction was identified initially using tandem affinity 
purification of double-tagged MNV VPg to identify specific 
binding partners in eukaryotic cell lysates [39]. The direct 
nature of the interaction was confirmed using purified 
recombinant proteins. The site of VPg interaction was 
mapped to the central 4GM fragment of eIF4G (residues 
652-1132) and alanine scanning mutagenesis of VPg 
suggested that residues in the C terminus made important 
contributions to binding affinity [39].  
The work described here extends these initial observations 
by providing a detailed characterisation of the interaction of 
MNV VPg with eIF4G. We describe a biochemical and 
biophysical dissection of the interaction using a 
combination of qualitative and quantitative binding assays, 
and NMR analyses to map precisely the particular regions 
of MNV VPg and eIF4G that mediate binding. We have 
discovered a C-terminal sequence motif in MNV VPg that is 
conserved in all noroviruses and is capable of 
Page%  %of% 3 21
Figure 2: MNV VPg interacts with eIF4GI and eIF4GII HEAT-1 domains via the C-terminal residues 
104-124.(A) SDS PAGE analysis of cobalt affinity pull-down assay using a GST-eIF4GI HEAT-1 
construct with a C-terminal His-tag as bait and either untagged MNV VPg(1-124) or MNV VPg(1-85) as 
prey. Protein mixtures are shown in lanes 1 and 2 (blue labels); bound proteins eluted with 250 mM 
imidazole are in lanes 3and 4 (red labels). (B) Sequence alignment showing the location of amino acid 
substitutions introduced into the C terminus of His-tagged MNV VPg. (C) SDS PAGE analysis of cobalt 
affinity assays using His-tagged MNV mutants (panel B) as bait and either GST-eIF4GI-HEAT-1 (top 
panel) or GST-eIF4GII-HEAT-1 as prey. Lanes 1-2: input proteins; lanes 3-11: eluted proteins. (D) SDS 
PAGE analysis of cobalt affinity pull-down assay using either His-tagged GFP-VPg(1-124) wild-type, 
GFP-VPg(1-124) F123A or a His-tagged GFP-VPg-NS6 fusion (containing the inactivating C139A 
mutation of the protease active site Cys (NS6 numbering)) as bait, and untagged eIF4GII HEAT-1 as 
prey. Lanes 1-3: protein mixes; lanes 4-6: protein eluted with 250 mM imidazole. 
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recapitulating the interactions made by MNV VPg with the 
translation initiation machinery in living cells. We further 
find that this motif binds to the HEAT-1 domains of eIF4GI 
and eIF4GII with micromolar affinity. Our evidence 
suggests that this VPg peptide motif may adopt a helical 
conformation when bound to eIF4G HEAT-1 and can 
mediate the formation of a ternary VPg-eIF4G-eIF4A 
complex with 1:1:1 stoichiometry in the presence of eIF4A. 
The functional significance of this interaction is evident 
from the observation that peptides corresponding to the 
eIF4G-binding motif of MNV VPg mediate an interaction 
with translation initiation complexes in cells that is 
indistinguishable from that made by the intact protein, and 
inhibit norovirus translation in vitro. Further our findings 
provide proof of principle that the VPg-eIF4G interaction 
might provide a useful target for antiviral drug 
development. The observation that the VPg-NS6pro 
precursor is unable to bind eIF4G shows that a free VPg C 
terminus is required for the interaction and suggests that 
proteolytic processing of the viral polyprotein precursor 
may be linked to the differential regulation of translation 
and RNA replication phases in the virus life cycle. Taken 
together our results provide significant new insights into the 
molecular mechanism of norovirus translational initiation 
mechanisms of noroviruses and identify an interaction 
interface that could be targeted for antiviral drug 
development.  
RESULTS 
MNV VPg binds to the eIF4G 4GM region via the eIF4G 
HEAT-1 domain. We previously showed that the binding 
site on eIF4GI for MNV VPg resides within the central 4GM 
fragment (residues 652 -1132; Fig 1A) [39]. This 4GM 
fragment contains a central HEAT-1 domain (residues 
751-1010), a crescent-shaped module comprised of 10 α-
helices [40], flanked by N- and C-terminal regions that are 
not known to be structured. To determine whether MNV 
VPg bound to the HEAT-1 domain we prepared GST-fusion 
proteins corresponding to sub-fragments of 4GM – the N- 
and C-terminal flanking regions (GST-4GM-N and 
GST-4GM-C respectively), and GST-eIF4G-HEAT-1 (Fig 
1A) – and used them as bait proteins in glutathione pull-
down assays to test their ability to interact with the viral 
protein (Fig 1B). These assays showed that GST-4GM and 
GST-eIF4G-HEAT-1 bound His-tagged MNV VPg with 
similar efficiency (lanes 7, 9) but that neither GST-4GM-N 
nor GST-4GM-C (or GST alone) had any detectable affinity 
for VPg (lanes 8, 10, 11). 
In a second set of pull-down assays, performed on cobalt 
affinity resin using His-tagged MNV VPg as the bait, the 
same pattern of binding was observed (see (Fig 1C)): 
GST-4GM and GST-eIF4G-HEAT-1 bound His-tagged MNV 
VPg equally well (lanes 10, 12) but there was no observed 
interaction with GST alone (lane 8). This experiment also 
showed that FCV VPg, which is only 27% identical in 
amino acid sequence with MNV VPg, does not interact with 
either GST-4GM or GST-HEAT-1 (lanes 9, 11).  
Together these results suggest that MNV VPg interacts 
with the HEAT-1 domain of eIF4GI. 
A conserved sequence at the C terminus of MNV VPg 
is critical for HEAT-1 domain binding. Previous work 
identified three mutations close to the C terminus of the 
124-residue MNV VPg, V115A, D116A and F123A, which 
all reduced its interaction with eIF4F [39]. This observation 
is likely due to the effect of the mutations on binding to 
eIF4G since the F123A mutation was also shown to 
substantially reduce binding of VPg to GST-4GM. The 
possible functional importance of the C terminus of MNV 
VPg was further underscored by alignment of VPg amino 
acid sequences from representative members of each of 
the norovirus genogroups, which revealed that residues 
108-124 are highly conserved (Supplementary Fig S1). 
Since our NMR studies of MNV VPg have shown that the 
C-terminal half of MNV VPg (residues 63-124) is flexible 
and exhibits no interaction with the structured core of the 
protein [34], the sequence conservation in this region 
probably reflects the functional constraint imposed by the 
interaction with eIF4G. We therefore hypothesized that 
VPg is likely to bind to eIF4G HEAT-1 via a contiguous 
sequence close to the C terminus. 
As a first test of this hypothesis, we compared the ability of 
MNV VPg proteins with and without the unstructured C 
terminus to bind to eIF4G HEAT-1. Using GST-eIF4GI 
HEAT-1 containing a C-terminal His-tag as the bait protein 
in a cobalt affinity pull-down assay, we found that it could 
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Figure 3: MNV VPg 104-124 interacts with the 
HEAT-1 domains of eIF4GI, eIF4GII and DAP5 with 
low micromolar affinity.  
(A-B) FITC-labelled peptides – MNV VPg(104-124) and 
MNV VPg(108-124) – were used in fluorescence 
anisotropy binding assays with unlabelled HEAT-1 
domains of eIF4GI (748-993), eIF4GII (745-1003) and 
DAP5 (61-323) in order to measure the affinity of the 
interaction. The normalised change in fluorescence 
anisotropy (relative to a no-protein control), ΔFA, is 
plotted against protein concentration. Error bars in ΔFP 
indicate the standard deviation of 5 (eIF4GI) or 10 
(eIF4GII) independent measurements. The solid lines 
indicate the fit to a single-site binding model. (A) 
Comparison of the binding of MNV VPg(104-124) and 
MNV VPg(108-124) to eIF4GI and eIF4GII HEAT-1 
domains. (B) Binding of MNV VPg(104-124) to the 
HEAT-1 domain of DAP5. The fit is calculated with the 
fluorescence anisotropy data from three independent 
experiments (all included in the graph). (C) ITC 
experiments in which unlabelled MNV VPg 1-124 was 
titrated into eIF4GII (745-1003). Top panel: raw data 
obtained for a representative experiment from 20 
injections (firstly with a volume of 0.5 µL followed by 19 
injections of 2 µL of eIF4GII HEAT-1). Bottom panel: the 
integrated data with a best-fit curve for the 
representative experiment generated for a single-site 
binding model using the Origin software package. 
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interact with untagged MNV VPg(1124) but not with MNV 
VPg(185), a truncated version of the protein that retains the 
helical core but lacks the unstructured C terminus (Fig 2A). 
This confirms that binding to eIF4G requires the C terminus 
of VPg.%
To map the extent of the MNV VPg C terminus needed to 
bind eIF4G we introduced blocks of 3-4 amino acid 
substitutions within and beyond the conserved sequence 
motif. In addition to the F123A mutation already known to 
reduce binding to eIF4G [39], we made the following 
mutations in His-tagged MNV VPg: 120KIN→120ESA, 
116DYGE→116RAPK, 112DRQV→112REAS, 
108WADD→108APRR, 104VGPS→104KKAH, and an insertion 
of GSGSGS after residue 103 (Fig 2B). Wild-type and 
mutant MNV VPg proteins were used as bait proteins in 
cobalt affinity pull-down assays to determine their ability to 
bind GST-eIF4GI and GST-eIF4GII HEAT-1 proteins, which 
are 83 % identical in amino acid sequence within this 
domain (Fig 2C). All mutations made in the conserved 
region (residues 108-123) had drastically reduced binding 
capacity for eIF4GI HEAT-1. However, neither the 
104VGPS→104KKAH mutations nor the GSGSGS insertion 
at position 103, which introduced substitutions at the N-
terminal end of the conserved motif, had any observable 
effect on MNV VPg binding to eIF4GI HEAT-1 (Fig 2C, 
upper panel). A very similar pattern of effects was observed 
when the MNV VPg mutants were tested for binding to 
GST-eIF4GII HEAT-1, with the exception that the 
104VGPS→104KKAH mutations were found to moderately 
reduce binding of the viral protein (Fig 2C, lower panel). 
These data are consistent with the hypothesis that the 
conserved motif within residues 108-124 of MNV VPg plays 
a critical role in eIF4G binding, and that the N-terminal 
boundary of the binding domain for eIF4GI and eIF4GII lies 
between residues 104 and 108.  
Finally, given that the eIF4G HEAT-1 binding site on MNV 
VPg is located very close to the C terminus of the protein, 
which is generated by proteolytic processing at the VPg-
NS6 junction within the virus polyprotein precursor, we 
asked whether the interaction with eIF4G HEAT-1 requires 
a free C terminus. To address this question we performed 
cobalt affinity pull down assays to compare the ability of 
eIF4GII HEAT-1 to bind wild-type his-GFP tagged MNV 
VPg and a his-GFP tagged MNV VPg-NS6 fusion protein 
which contained a C139A mutation in the NS6 protease to 
prevent auto-processing of the VPg-NS6 junction; (the GFP 
tags are not relevant to this assay – they were added in 
anticipation of using these reagents for other experiments 
that were not performed). We found that wild-type his-GFP-
VPg was effective at capturing eIF4GII HEAT-1 in these 
assays but his-GFP-VPg-NS6 had no observable binding 
activity (Fig 2D). The fusion protein exhibited the same lack 
of binding activity as the his-GFP-VPg (F123A) mutant, 
which was used as a negative control (Fig 2D). This result 
suggests that processing of the VPg-NS6 junction is 
required for the MNV VPg-eIF4G interaction. 
The C terminus of MNV VPg binds eIF4G HEAT-1 
domains with micromolar affinity. The results described 
above indicate that a contiguous region at the C terminus 
of VPg mediates binding to the eIF4G HEAT-1 domain. To 
determine the affinity of the interaction, we used peptides 
corresponding to the MNV VPg C terminus in fluorescence 
anisotropy experiments. Peptides corresponding to MNV 
VPg 104-124 and 108-124 and incorporating an N-terminal 
FITC group were chemically synthesized and tested for 
binding to untagged versions of the HEAT-1 domains of 
eIF4GI (748-993) and eIF4GII (751-1003) (see Materials 
and Methods). In addition, we tested the binding of these 
peptide to the HEAT-1 domain of DAP5 (61-323), which 
shares approximately 40% amino acid sequence identity 
with the HEAT-1 domains of eIF4GI and eIF4GII and is 
very similar in structure [41].  
In a first set of experiments, we compared binding of the 
two MNV VPg peptides to eIF4GII HEAT-1. These showed 
that MNV VPg 104-124 binds with a KD of 2.8 µM, while the 
shorter MNV VPg 108-124 peptide binds with about four-
fold weaker affinity (KD = 10.6 µM) (Fig 3A). Very similar 
affinities for these two peptides were observed in 
experiments performed with the fusion protein MBP-
eIF4GII HEAT-1 (Supplementary Fig S2). These results are 
consistent with the pull-down experiments, which found 
that mutations on the C-terminal side of position 104 in 
VPg (104VGPS→104KKAH) reduced binding to eIF4GII, 
whereas the 103GSGSGS insertion immediately before 
position 104 did not (Fig 2C). %
All subsequent binding experiments were performed with 
the tighter-binding MNV VPg 104-124 peptide. It was 
observed to bind with essentially identical affinity to the 
HEAT-1 domains of eIF4GII (KD = 2.8 µM) and eIF4GI 
(KD = 3.0 µM) (Fig 3A). However MNV VPg(104-124) 
bound about six-fold less well to the DAP5 HEAT1 domain 
(KD = 19.9 µM) (Fig 3B). This difference in affinity suggests 
that VPg is more likely to recruit eIF4GI and eIF4GII in 
infected cells than DAP5 and may explain why DAP5 was 
not observed as a ligand for MNV VPg in the tandem-
affinity purifications that were used originally to identify 
eIF4G as a direct ligand in cell lysates [39].  
To determine the binding affinity of full-length MNV VPg for 
eIF4GII HEAT-1 interaction we used isothermal titration 
calorimetry (ITC). In these experiments, small volumes of 
untagged eIF4GII HEAT-1 were injected into a 200 µL 
sample of untagged MNV VPg(1-124); the heat changes 
arising from the interaction of the two proteins were 
measured and fitted to a single-site binding model (Fig 3C). 
The KD determined from three independent ITC 
experiments was 5.2 µM. This value is comparable to the 
KD obtained from fluorescent anisotropy measurements 
performed with the MNV VPg(104-124) peptide (2.8 µM) 
and strongly suggests that MNV VPg residues outside the 
C-terminal region do not contribute significantly to eIF4G 
binding. 
The direct interaction between VPg and eIF4GI HEAT-1 
is conserved in noroviruses. Having established that the 
C terminus of MNV VPg could mediate binding of the 
protein to eIF4G HEAT-1 domains with micromolar affinity, 
we sought to test how well this function is conserved in 
related viruses. This seemed likely since 10 out of the 21 
residues in the region defined by MNV VPg 104-124 are 
strictly conserved in all norovirus genogroups 
(Supplementary Fig S1). Intriguingly, there also appears to 
be significant conservation of the eIF4G-binding motif in 
the C terminus of human astrovirus 4 – 11 out of 23 
residues are identica; – while there is very little indication of 
the occurrence of the motif in the C terminus of VPg from 
FCV, a member of the Vesivirus genera of the Caliciviridae 
family (Fig 4A). To investigate the eIF4G-binding properties 
of these various VPg proteins we fused C-terminal 
sequences corresponding to the sequences that aligned 
with residues 102-124 from MNV VPg to GST (Fig 4A). The 
resulting GST-VPg fusion proteins included C-terminal VPg 
sequences from norovirus genogroups GI, GII, GIII and GV 
(MNV), from FCV F9 and from human astrovirus 4 (Fig 4A) 
and were used as prey in cobalt affinity pull-down assays 
to determine whether they bound to His-eIF4GI HEAT-1, 
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which was used as bait. All of the norovirus VPg GST 
fusions were found to interact with eIF4GI HEAT-1, 
similarly effectively (lanes 4-7), while neither FCV nor 
human Astrovirus 4 GST-VPg fusions (lanes 8, 9) were 
observed to bind (Fig 4B). This strongly suggests that 
direct binding to eIF4G is a conserved function of the C 
terminus of norovirus VPg proteins. The interaction 
appears to be specific since partial conservation of the 
eIF4G-binding motif in human astrovirus 4 VPg was not 
sufficient to permit binding. The negative result for FCV 
VPg is consistent with previous work which has shown that 
it interacts directly with eIF4E and that, in contrast to MNV, 
FCV translation initiation is inhibited in the presence of the 
eIF4E regulatory protein, 4E-BP1 [27,37]. 
MNV C terminus may adopt a helical conformation 
when bound to eIF4G HEAT1. To begin to probe the 
structural basis of the interaction between MNV VPg and 
eIF4G HEAT-1, we used GST-fusions with MNV VPg 
102-124 to test the contribution to binding of specific amino 
acids in the C terminus of VPg. In an initial series of 
experiments we mutated conserved residues within the 
motif that is responsible for binding to eIF4G; these 
included W108A, V115A and the double-mutation D110A-
D111A. The effects of the mutations were tested using His-
eIF4GI HEAT-1 as the bait protein in a pull-down assay. In 
each case the mutation was found to abrogate binding (Fig 
4C; lanes 5-7).  
The results of these mutagenesis experiments, along with 
the previous observation that the F123A point mutation 
also severely reduces binding (Fig 2C), were intriguing 
since they suggested that the binding activity is distributed 
throughout the conserved motif within residues 108-124 of 
MNV VPg. Since this motif is 17 amino acids long and is 
found in an unstructured C terminus in the free protein [34], 
the fact that single point mutations within it (W108A, 
V115A, F123A) all severely reduced binding suggested that 
the interaction with eIF4G is unlikely to involve the C 
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Figure 4: The C-termini of Noroviral VPg proteins contain a conserved sequence motif that binds to eIF4G HEAT-1. (A) Top: Amino acid sequence 
alignments of representative sequences of the C-termini of all 6 genogroups of Norovirus (GI-GIV). Second from top: Alignment of the C-termini of Human 
Astrovirus 4 (HuAST4) VPg with MNV (GV) VPg. Third from top: Alignment of the C-termini of FCV VPg with MNV (GV) VPg. Bottom: Alignment of the C 
terminus of MNV (GV) VPg with Rice Yellow Mottle Virus (RYMV) VPg. The representative strains used in the alignments are GI - Hu/GI/Norwalk/1968/US, 
(NCBI accession AAC64602), GII - Lordsdale virus Hu/GII/Lordsdale/1993/UK (NCBI accession P54634), GIII - Bo/GIII/B309/2003/BEL (NCBI accession 
ACJ04905.1), GIV - Hu/GIV.1/LakeMacquarie/NSW268O (NCBI accession AFJ21375), GV - Mu/NoV/GV/MNV1/2002/USA (NCBI accession ABU55564.1), 
GVI - dog/GVI.1/HKU_Ca035F/2007/HKG (NCBI accession FJ692501), FCV - F9 strain (NCBI accession P27409.1), HuAst4 - Human astrovirus 4 (NCBI 
accession Q3ZN07), Rice yellow mottle virus isolate CI4 (NCBI accession NC_001575). Sequence alignments were performed by ClustalW [6] and BioEdit 
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html). #Denotes sequences that were used in pull-down assays (see panel B). (B) The indicated VPg sequences in 
panel A were fused to the C terminus of GST for use as prey in cobalt affinity pull-down assays in which His-tagged eIF4GI HEAT-1 was used as bait, and 
analysed by SDS PAGE. Lanes 1-3: input samples of some the proteins used in pull-down experiments (black labels); lanes 4-11: eluted proteins (red labels; 
bands at ~27 kDa indicate GST-VPg C-terminal constructs that bound to His-eIF4G HEAT-1); lanes 12-19 (blue labels) – protein mixes used in the pull-down 
experiments. (C, D) Mutational analysis of the C-terminal sequences of MNV VPg were performed using GST-MNV VPg C-terminal fusions in the same way 
as the experiment presented in panel B. Labelling is colour-coded as in panel B. (E) Helical wheel representation of MNV VPg 102-124 generated using 
http://heliquest.ipmc.cnrs.fr/ [42]. Residues mutated for the pull-down assays are indicated by bold-face labels and colour-coded by the effect of the 
substitution on binding to eIF4G HEAT-1: red – no binding; black –binding at or near wild-type levels.
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terminus of VPg lying in an extended conformation across 
the surface of the HEAT-1 domain. For such a mode of 
binding, individual point mutations would be unlikely to 
completely abrogate binding, particularly for mutations at 
the extremities of the motif. However, the strong effects of 
point mutations might be rationalised if the MNV VPg C 
terminus adopts a rigid structure upon interaction with 
eIF4G. Consistent with this idea, a helical wheel 
representation of the MNV VPg C terminus suggests that 
the mutations tested in the first series of experiments 
described above (and F123A), would all be on the same 
side of an α-helix (Fig 4E). This model suggests that there 
would be an interacting flank (containing W108, V115 and 
F123) and a non-interacting flank. It also predicts that the 
reduction in binding observed for the D110A-D111A double 
mutation is likely to be attributable to the effects of the 
D111A substitution since it lies on the interacting flank of 
the helix.   
To test the possibility that the C terminus of VPg may adopt 
a helical conformation upon interacting with eIF4G HEAT-1, 
we prepared a second set of mutations in the context of our 
GST-MNV VPg (102-124) fusion protein for use in pull-
down assays: D110A, R113A and K120A. Although these 
mutations are distributed throughout the conserved eIF4G-
binding motif in MNV VPg, they were all predicted to be on 
the non-interacting flank of the putative helix. As can be 
seen in Fig 4D, GST-MNV VPg (102-124) fusions 
containing D110A, R113A, and K120A mutations are all 
capable of binding eIF4GI HEAT-1 (lanes1-3). Of these, 
only the K120A mutant appears to bind as effectively as the 
wild-type sequence; although the binding of the D110A and 
R113A mutants appears to be slightly weakened, they still 
bind much more effectively than the F123A mutant (lane 4). 
These results are consistent with the hypothesis that the C 
terminus of MNV VPg adopts a helical conformation upon 
interaction with eIF4G and suggest that the helical flank in 
contact with eIF4G contains residues W108, D111, V115 
and F123. Confirmation of this model requires further 
structural analysis, but if it is confirmed the helical mode of 
binding would likely apply to all other norovirus VPg 
proteins since the sequence of the eIF4G-binding motif is 
highly conserved (Fig 4A).  
Mapping the MNV VPg binding site on eIF4G HEAT-1. 
To further probe the molecular details of the MNV VPg-
eIF4G interaction we used nuclear magnetic resonance 
(NMR) spectroscopy to map the VPg binding site on the 
HEAT-1 domain. 1H15N TROSY NMR experiments were 
used to monitor chemical shift perturbations in the spectra 
obtained from a solution of 15N labelled eIF4GI HEAT-1 
domain as it was titrated with a synthetic unlabelled peptide 
corresponding to MNV VPg(104-124). We used the 
backbone resonance assignments of eIF4GI HEAT-1 
deposited in the Biological Magnetic Resonance Data Bank 
[43] to assign changes that occurred in the 1H-15N TROSY 
NMR spectra on formation of the VPg(104-124):eIF4GI 
HEAT-1 complex to particular residues in HEAT-1.  
Ideally in such experiments a limited number of amide (HN) 
resonances would shift (in fast or slow NMR time scales) in 
a dose-dependent manner. Since the spectra are 
dominated by signals from backbone amides (though they 
also contain peaks from side-chain amides in Asn, Gln, Arg 
and Trp residues), they can be used to map ligand binding 
sites. Typically clusters of surface residues that are 
affected by titration of the ligand are presumed to define 
the likely binding surface. However, titration of the VPg 
peptide into 15N labelled eIF4GI HEAT-1 was found to 
cause significant perturbations of most of the HN 
resonances, which indicates that binding of VPg affects the 
entire HEAT-1 domain. The exact nature of these 
conformational changes in HEAT-1 cannot yet be 
determined precisely, though they are likely to be relatively 
subtle since the domain retains the capacity to interact with 
eIF4A, which requires a large binding interface (see below 
and Fig 5C). As a result of the extensive perturbations, the 
spectrum observed at the end point of the titration (1.35 
peptide:protein molar ratio) was very different to the 
reference spectrum obtained before the start of the titration 
(Fig 5A, Supplementary Fig S3). Moreover, many of the 
affected resonances appeared to enter a dynamics regime 
dominated by conformational exchange on slow or 
intermediate time scales, since HN peaks disappeared 
from the HSQC as the titration proceeded. While some new 
peaks appeared later in the titration, it was not possible to 
relate these to the peaks that had disappeared earlier in 
the titration (Supplementary Fig S3).  
However, from closer inspection of HSQC spectra it is clear 
that a limited number of peaks are selectively broadened 
very early in the titration (Fig 5A). Since these changes 
happen at low peptide concentrations, they probably 
indicate specific contacts made by the viral protein on the 
eIF4GI HEAT-1 domain. To obtain a quantitative 
understanding of how specific HN resonances were 
changing early in the titration, the volume of non-
overlapped peaks in the HSQCs were determined for both 
the reference spectrum (eIF4GI HEAT-1 only) and the 
spectrum obtained after addition of 0.35 molar equivalents 
of peptide. Volume ratios of matching peaks in the two 
spectra were calculated for each assigned residue (Rv = |
Reference peak vol|)/(|0.35 eqv peak vol|) (Fig 5B). Since 
the number of scans recorded for the reference and for the 
0.35 molar equivalent HSQC spectra were 16 and 28 
respectively and the total volumes are not significantly 
different, Rv should be √(16/28) (= 0.76) for unperturbed 
residues. The only HN resonances for which this ratio is 
approximately 0.76 are at the N- and C-termini of the 
domain (residues 749-973 and 977-993) and within the 
loop formed by residues 869-880 of the molecule, which is 
in a disordered region in the eIF4GII HEAT-I crystal 
structure [40]; these features appear not to interact with the 
MNV VPg C-terminal peptide. Most other residues have 
higher values of Rv, as expected from the large number of 
perturbations caused by peptide binding. However, a small 
number of resonances deviate substantially from this 
expected value. In particular HN resonances from residues 
807, 823, 825, 826, 851, 896-898, 904, 912, 914, 917-921, 
935, 939 and 950 all have ratios that are more than 6 times 
greater than the expected value.  
The position of these residues in a homology model of the 
eIF4GI HEAT-1 domain is given in Fig 5C. Several of these 
residues (823, 917, 920, and 921) are internal and 
probably suffer chemical shift perturbations because of 
conformational adjustments induced by binding of MNV 
VPg. Most of the other residues with very large Rv values 
cluster in two surface patches in the middle of the eIF4GI 
HEAT-1 domain, one formed by residues L897 and L939, 
which are close to the binding site for eIF4A, and one 
containing residues L912, E914, H918 and D919, which 
are on the opposite face of HEAT-1. Clearly, surface 
residues are more likely to be able to make direct contact 
with the bound MNV VPg peptide.  
To confirm whether resonance perturbations assigned to 
residues that cluster in the surface patches in the middle of 
the HEAT-1 domain are involved in direct contact with MNV 
VPg, we tested the effect of point mutants on binding of the 
viral protein. The following mutations were made in eIF4GI 
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HEAT-1: L897A and L939A in the cluster proximal to the 
eIF4A binding site, and L912A, H918A, D919R, and L939A 
in the distal cluster. (A fifth mutation in the distal cluster, 
E914R, was also prepared but found to have picked up an 
additional mutation – presumably due to a PCR error –
 resulting in the substitution K901M which is adjacent to the 
proximal cluster; this E914R/K109M double mutant 
therefore changes both putative VPg-binding sites). As a 
negative control we also made the eIF4GI HEAT-1 (K771A) 
mutant since this residue is in the N terminus of the 
HEAT-1 domain and was found in our NMR analysis to be 
unaffected by binding of MNV VPg (Rv = 0.55). 
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Figure 5: NMR chemical shift mapping reveals the binding site for MNV VPg on the eIF4GI HEAT-1 domain. (A) 
Superposition of the 1H15N TROSY HSQC spectra of 15N-labelled eIF4GI HEAT-1 (748-993) obtained in the absence 
(black) and presence (green) of 0.35 molar equivalents of unlabelled MNV VPg(104-124) peptide. (1H15N TROSY NMR 
spectra for all of the points in the titration are given in Supplementary Figure 3). The residues for which the intensity of 
amide 1H15N signals exhibit the greatest reductions as the MNV VPg(104-124) peptide concentration is increased are 
indicated by their residue number. The assignments were taken from the Bio Magnetic Resonance Database (BMRB id 
18738). (B) Plot of the ratio of the absolute values of non-overlapping peak volumes for assigned residues obtained at 0 
and 0.35 molar equivalents of the MNV VPg(104-124) peptide. High values of the ratios indicate the residues in eIF4GI 
HEAT-1 most affected by MNV VPg binding. The red dashed line indicates the expected volume ratio (Rv) for unperturbed 
residues was 0.76 based on the relative number of scans performed in each HSQC experiment. Points above the green 
dashed line indicate residues for which the peak volume ratio was at least six times higher than the baseline for 
unperturbed amides. (C) Model of the complex of eIF4GI HEAT-1 (grey, surface representation) and eIF4A (cyan, cartoon 
representation) indicating the predicted location the VPg binding. Surface residues in eIF4GI HEAT-1 that exhibit the 
greatest changes in Rv in the presence of the MNV VPg(104-124) peptide are coloured yellow. The model of eIF4GI 
HEAT-1 was generated using SWISS-MODEL [44]; the complex was created by superposing this model on the eIF4G 
HEAT-1 component of the yeast eIF4G-eIF4A co-crystal structure [45]. (D) SDS PAGE analysis of pull-down assays to test 
the effect of mutations in the putative VPg-binding site on eIF4G HEAT-1 on binding to the viral protein. His-tagged MNV 
VPg(1-124) was used as bait; eIF4GI HEAT-1 wild-type or mutant proteins were used as prey, and the pull-down buffer 
contained 150 mM NaCl (top panel) or 300 mM NaCl (bottom panel). Lanes 1-8 (blue labels): input protein mixtures; lanes 
9-16 (red labels): eluted proteins. (E) Graphical representation of the results of the cobalt affinity pull-down assays 
performed in the presence of 150 or 300 mM NaCl, plotted as the ratio of the optical densities of the eIF4GI HEAT-1 band 
to that of the His-MNV VPg band in eluted fractions (lanes 9-16 in panel D). Band densities were quantified using ImageJ 
(http://imagej.nih.gov/ij/) and the ratios were normalised to the wild-type control. 
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The VPg-binding ability of these eIF4G mutants was tested 
in a cobalt affinity pull-down assay in which His-MNV 
VPg(1-124) was used as bait. A first series of assays was 
performed using a binding buffer containing 150 mM NaCl 
(see Materials and Methods). This demonstrated that the 
H918A mutation in the distal cluster had the most severe 
defect in MNV VPg binding, reducing it to less than 10% of 
the control, while nearby substitutions D919R and L939A 
showed more modest decreases in binding (Fig 5D-E). 
Within the proximal cluster, the L897A mutation had no 
effect on binding, while the L939A mutation reduced 
binding to about 60% of the control value. To increase 
sensitivity, a second series of assays was performed in 
buffer containing 300 mM NaCl. Under these higher-salt 
conditions, binding defects due to the mutations were more 
pronounced. The H918A mutant was again found to exhibit 
the weakest binding of MNV VPg, but the deleterious 
effects of the E912R and D919R mutations were more 
severe. In the proximal cluster, there was still no effect of 
the L897A mutation but the binding defect due to the L939A 
mutation was slightly worse. The interaction of VPg with 
the E914R/K901M double mutant, which was similar to 
wild-type at 150 mM NaCl, was reduced significantly at a 
salt concentration of 300 mM. Finally, as expected, the 
negative control mutation K771A had no effect on binding 
at low or high salt (Fig 5D-E).  
These results are consistent the location of the MNV VPg 
binding site on eIF4GI HEAT-1 that was mapped in NMR 
titration experiments. They also suggest that the binding 
site is centred on the surface patch (around residues 
914-919) distal to the eIF4A binding site. The binding site 
may extend to residue L939 but residue L897, which did 
not affect binding of VPg when mutated and is closest to 
the binding site of eIF4A, may define an upper boundary of 
the VPg binding site. It is perhaps worth noting that if 
residues 108-124 of MNV VPg were to form a helix on 
binding to eIF4G (see above), the helix would have five 
turns and therefore be of a similar length to the helices in 
the HEAT-1 domain.  
MNV VPg forms a stable complex with eIF4A and eIF4G 
HEAT-1 at a stoichiometry of 1:1:1. The VPg-binding site 
on eIF4GI identified by our NMR and mutagenesis 
experiments lies on a surface of the HEAT-1 domain that is 
distinct from the eIF4A-binding site. This suggested to us 
that VPg binding would not interfere with the eIF4G-eIF4A 
and that MNV VPg might therefore be able to form a 
ternary complex with eIF4G and eIF4A. The presence of 
eIF4A in initiation complexes formed with MNV VPg is 
consistent with earlier observations that MNV VPg 
translation is sensitive to inhibition of the ATPase activity of 
eIF4A by hippuristanol [27].  
We used size exclusion chromatography (SEC) to 
characterise the complexes formed by MNV VPg and 
eIF4A with eIF4GI HEAT-1. Stoichiometric mixes of MNV 
VPg and eIF4GI HEAT-1, and eIF4A and eIF4GI HEAT-1 
both resulted in peaks that eluted at lower volumes (14.7 
and 14.3 mL respectively) than observed for the individual 
component proteins, consistent with the formation of binary 
complexes (Fig 6A). The presence of these complexes was 
confirmed by SDS PAGE analysis (Fig 6A inset). An 
equimolar mix of 1:1:1 MNV VPg, eIF4GI HEAT-1, and 
eIF4A eluted at an even lower volume (13.6 mL), 
consistent with the formation of a complex involving all 
three proteins, an interpretation that was also confirmed by 
SDS PAGE analysis (Fig 6A).  
The SEC analysis was coupled to multi-angle laser light 
scattering (SEC-MALLS) to measure the molecular weights 
(MW) of these complexes and determine their 
stoichiometry (Fig 6B). For the VPg:eIF4G HEAT-1 
complex the observed MW (45.9 kDa) was very close to 
that expected for a 1:1 complex (46.5 kDa). For the 
eIF4A:eIF4G HEAT-1 complex the observed 65.9 kDa MW 
was somewhat lower than the 79.7 kDa expected for a 1:1 
complex. The reason for this small discrepancy is not clear 
– it may be due to partial dissociation during elution – but 
the formation of a 1:1 binary complex is still the most likely 
outcome. The average MW measured for the ternary MNV 
VPg:eIF4A:eIF4GI HEAT-1 complex using SEC-MALLS 
was 94.5 kDa, which is very close to the 94.1 kDa 
expected for a complex of 1:1:1 stoichiometry. The 
formation of this ternary complex is consistent with the 
observation that MNV VPg and eIF4A have non-
overlapping binding sites on the eIF4G HEAT-1 domain. 
This observation also helps to explain how MNV VPg is 
able to interact with functional eIF4E:eIF4G:eIF4A 
complexes, as shown by the ability of the protein to interact 
with these proteins in cell lysates [39]; the eIF4E binding 
site on eIF4G is upstream of the HEAT-1 domain within 
eIF4G [9], allowing eIF4E to bind independently of eIF4A 
and MNV VPg. 
MNV VPg C-terminal peptide fusions inhibited MNV 
VPg mediated translation in vitro but could not be 
shown to have any anti-viral activity. Our in vitro binding 
studies have shown that a conserved motif within the C 
terminus of MNV VPg mediate a micromolar affinity 
interaction with the HEAT-1 domain of eIF4GI and eIF4GII, 
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Figure 6: MNV VPg forms a ternary complex with eIF4G and eIF4A. 
(A) SEC profiles monitored by differential refractive index (which is 
proportional to protein concentration) for eIF4A, eIF4G HEAT-1 and MNV 
VPg as well as for the binary complexes formed by mixing approximately 
equimolar quantities of eIF4A and eIF4G HEAT-1 (4A-4G), eIF4G 
HEAT-1 and MNV VPg (4G-VPg), and the ternary complex obtained from 
eIF4A, eIF4G HEAT-1, and MNV VPg (4A-4G-VPg). SDS PAGE analysis 
of peak fractions of the binary and ternary complexes obtained in the 
SEC experiments are also shown in A. (B) SEC-MALLS analysis of the 
molar mass distributions of the binary and ternary complexes plotted 
against the SEC profiles shown in A. 
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possibly by adopting a helical conformation that interacts 
with a centrally-located binding site that does not overlap 
with the binding site for eIF4A. To probe the physiological 
significance of this observation we tested whether GST-
fusions containing the C terminus of MNV VPg could inhibit 
norovirus translation. To do so we performed in vitro 
translation assays programmed with VPg-linked genomic 
RNA in the presence of increasing concentrations of GST-
MNV VPg(102-124) or the GST-MNV VPg(102-124) F123A 
mutant, which binds eIF4G much more weakly. As shown 
in Fig 7A GST-MNV VPg(102-124) inhibits norovirus 
translation in a dose-dependent manner. At the highest 
concentration used (28 µM) the yield of translation product 
is reduced to 40% of the control value. In contrast, at all 
concentrations the non-binding GST-MNV VPg (102-124) 
F123A mutant causes no significant inhibition on 
translation.  
As a further test of the specificity of the inhibition of VPg-
mediated translation the same proteins were used at the 
same concentrations in alterative in vitro translation 
assays. These were programmed with a capped bicistronic 
construct containing an open reading frame (ORF) for 
chloramphenicol acetyl transferase (CAT) under the control 
of an m7G cap and a downstream luciferase (LUC) ORF 
under the control of an IRES. Two different constructs were 
tested, one with a FMDV IRES and the other with a PTV 
IRES. We found that neither the wild-type nor the F123A 
mutant form of GST MNV VPg (102-124) had any effect on 
translation of either CAT or LUC at even the highest protein 
concentrations, irrespective of the type of IRES present 
between the cistrons (Fig 7B, Supplementary Fig S4). This 
suggests that the inhibition of VPg-dependent translation 
by exogenous added GST-MNV VPg(102-124) is specific. 
It is likely mediated by competition for binding to eIF4G. %
As a second probe of the physiological relevance of our 
observation that the C terminus of MNV VPg mediates 
binding of the protein to eIF4G, we tested whether MNV 
VPg(102-124) could interact with the large ribosomal 
initiation complexes in eukaryotic cells, as has been 
previously demonstrated for TAP-tagged MNV VPg(1-124) 
[39]. To do this plasmids encoding mCherry-MNV 
VPg(102-124) and mCherry-MNV VPg(102-124) F123A 
fusion proteins were expressed in BV2 macrophages using 
lentivirus vectors (see Materials and Methods). Cell lines 
expressing mCherry MNV VPg(102-124) wild-type or the 
F123A mutant were selected on the basis of equal 
fluorescence intensity. Subsequent α-mCherry co-
immunoprecipitation and western blot analysis revealed 
that eIF4G, eIF4A, eIF4E, eIF3D and PABP all co-
immunoprecipitate with wild-type mCherry MNV 
VPg(102-124) but not with the F123A version (Fig 8A). This 
suggests that the MNV VPg C-terminal peptide can form 
the same complexes in the cytosol as the full-length 
protein.  
Finally, since we had shown that MNV VPg(102-124) can 
inhibit noroviral translation in vitro and interacts specifically 
with initiation complexes in cells, we sought to determine 
whether cells over-expressing mCherry MNV 
VPg(102-124) are resistant to infection by the virus. 
However, no difference was observed in MNV titre over a 
24-hour time course between cells expressing mCherry 
MNV VPg (102-124), or the non-binding mCherry-MNV 
VPg (102-124) F123A mutant or mCherry alone (Fig 8B).  
Page%  %of% 10 21
Figure 7: GST-MNV VPg 102-124 inhibits MNV VPg-mediated translation in vitro but not cap-dependent or IRES-dependent translation. In vitro 
translation reactions were performed in the presence of increasing concentrations of GST-MNV VPg(102-124) WT protein or the GST-MNV VPg(102-124) 
F123A mutant that binds much less well eIF4G. Protein synthesis was monitored by autoradiography of SDS PAGE analysis of incorporation of 35S-
methionine in translation reactions. (A) Top panel: Effect of exogenous GST-MNV VPg(102-124) proteins on translation from VPg-linked MNV RNA; bottom 
panel: quantitative analysis of the level of 35S-methionine incorporation. (B) Top panel: Effect of exogenous GST-MNV VPg(102-124) proteins on translation 
from capped bi-cistronic mRNA constructs containing the FMDV IRES between the first (CAT) and second (Luc) cistrons; bottom panel: quantitative analysis 
of the level of 35S-methionine incorporation. 
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The mCherry tag adds more than 25 kDa to the molecular 
weight of the peptide. The lack of inhibition of norovirus 
replication might therefore be due to the copy number of 
the molecule in cells being too low. As an alternative test of 
the inhibitory activity of the MNV VPg C terminus wild-type 
and F123A variants of the MNV VPg(102-124) that 
incorporated N-terminal cell penetrating peptide (CPP) 
sequences were synthesised. Two different CPP 
sequences were used, derived from HIV TAT and Bac7. In 
each case the peptides were also N-terminally tagged with 
FITC so that penetration into cells could be monitored with 
fluorescence microscopy. As shown in Fig 8C and 
Supplementary Fig S5A, the peptides were able to get into 
the cytoplasm. However, no difference was observed in 
viral titre over a 24-hour time course between cells 
containing either wild-type or F123A versions of the cell 
penetrating VPg peptides when compared to controls that 
had only been exposed to the peptide solvent, DMSO (Fig 
8D and Supplementary Fig S5B). The reason for the 
negative result is not clear although it may again be due to 
delivery of insufficient peptide to the cell interior.  
 
Discussion 
It has been known for nearly 20 years that the VPg protein 
covalently attached to the 5´-end of calicivirus RNA 
genomes is critical for translation [28]. Since then, various 
interactions of VPg proteins with eukaryotic initiation 
factors, including eIF3, eIF4E and eIF4G, have been 
reported [27,35-37,39]. Of these, the interaction of FCV 
VPg with eIF4E and of MNV VPg with eIF4G appear to be 
the most functionally significant [27,39] but mechanistic 
details beyond the idea that VPg serves to recruit the viral 
RNA to the translation machinery have been lacking.  
In this paper we report the discovery and characterisation 
of a conserved ~20 amino acid motif in the C terminus of 
norovirus VPg proteins that binds to the HEAT-1 domains 
of eIF4GI and eIF4GII with micromolar affinity, an 
interaction that is crucial for the initiation of translation from 
the viral RNA genome. Norovirus VPg therefore serves as 
a proteinaceous ‘5´-cap’ that does not require a functional 
interaction with the cap-binding protein, eIF4E [27]. Our 
data provide clear evidence for the mechanistic basis for 
an important and unusual paradigm of translation initiation 
that is independent of 5´-cap and IRES structures, and 
place functional and geometric constraints on how it 
operates.  
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Figure 8: mCherry-MNV VPg(102-124) co-immunoprecipitates with translation initiation proteins.(A) RFP-Trap® 
immunoprecpitation of lysates of BV2 cells expressing mCherry, mCherry-MNV VPg(102-124) WT or mCherry-MNV VPg(102-124) 
F123A. Pre-purification lysates (input), purified fractions (IP) and unbound fractions (Flow through) were analysed by SDS PAGE 
and western blotting. (B) Time course of BV2 infection (MOI 0.01 TCID50 units/cell) with MNV1 in the presence of mCherry-VPg 
proteins. Prior to infection BV2 cells were transduced with lentiviruses expressing mCherry, mCherry-MNV VPg(102-124) WT or 
mCherry-MNV VPg(102-124) F123A. The progress of infection was monitored by measuring the number of viral cDNA copies 
generated from quantitative RT-PCR analysis of whole-cell RNA. (C) Fluorescence microscopy analysis of cell penetration of the 
FITC-TAT-MNV VPg(102-124) peptides. The images shown are merged images of DAPI stained nuclear DNA (blue) and wild-type 
or F123A versions of the cell penetrating peptides (green). (D) Time course of BV2 infection (MOI 0.01 TCID50 units/cell) with MNV1 
following pre-treatment for 150 minutes with 100 µM of wild-type or F123A versions of the cell penetrating peptides prior to 
infection. The progress of infection was monitored by RT-PCR analysis (as in panel B).
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We have shown that the equilibrium dissociation constant 
for binding of the C terminus of VPg for the eIF4G HEAT-1 
domains is in the low micromolar range – around 3 µM (Fig 
3). This is relatively weak when compared to the affinity of 
m7G capped mRNA for the eIF4F complex which is in the 
low nanomolar range [46]. IRES RNA structures are also 
reported to bind to initiation factor complexes with affinities 
in the low nanomolar range [47-49]. At first sight it may 
therefore appear questionable whether the binding of MNV 
VPg to eIF4G HEAT1 is of high enough affinity to recruit 
the ribosome, particularly if it is in competition with 5´-
capped eukaryotic mRNAs. However, it seems likely that in 
infected cells the VPg:HEAT-1 interaction forms just one 
contact in the overall interaction between VPg-linked 
genomic RNA and the initiation machinery, though we 
suspect that these points of contact remain focused on 
eIF4G. Although initial interaction of the viral RNAs with 
eIF4F leads to recruitment of eIF3 and the 40S ribosomal 
subunit, and there is evidence that norovirus VPg can bind 
to both eIF4E [37] and eIF3 [35,36], the functional 
significance of these interactions has yet to be 
demonstrated. Indeed, although there is residual binding of 
MNV VPg to eIF4E when the eIF4G binding site on the 
viral protein has been mutated, abrogation of eIF4E-
dependent translation initiation, either through the addition 
of the 4E-binding protein or cleavage of eIF4G by the 
FMDV L protease, has no effect on translation of MNV 
VPg-linked RNA [27].  
It seems more likely that RNA interactions play a significant 
role in the formation of initiation complexes with VPg-RNA, 
since capped and uncapped mRNA can both bind to eIF4F 
with nanomolar affinity [46], mostly likely though 
interactions with RNA binding sites on eIF4G and eIF4A 
[40]. Although the cap adds little to the overall affinity, it 
may serve to specify the orientation of cellular mRNA 
binding to eIF4F since the interaction with RNA is not 
otherwise sequence-specific. It may be that VPg is acting 
in a similar mechanism to the m7G cap, providing an 
important topological constraint for a high-affinity 
interaction between noroviral RNA and the eIF4F complex 
to ensure efficient initiation.  
The precise geometry of the complex formed when 
noroviral RNA binds to eIF4F is difficult to determine. 
Although there is a crystal structure for the binary complex 
comprising eIF4A and the HEAT-1 domain of eIF4G [45] 
and we have at least partially mapped the binding site on 
eIF4G HEAT-1 for the conserved C-terminal peptide in 
MNV VPg (Fig 5), the C terminus of VPg is linked flexibly to 
the helical core of the protein (residues 11-62) which 
contains the covalent point of attachment (Tyr 26) of the 
viral RNA [34]. Since the AUG start codon in noroviral RNA 
is only 4 nucleotides from the 5´-end, the length of this 
linker may be required to permit positioning of the start 
codon in the ribosomal P-site without it being encumbered 
by the bulk of the eIF4F complex. Similar considerations 
apply to all noroviruses since the key functional features –
 proximity of the start codon to the 5´-end of the viral RNA, 
site of RNA attachment to VPg and length of the linker to 
the conserved eIF4G-binding motif – are conserved. 
However, high-resolution structural analyses will be 
required to establish the relative positions of norovirus 
VPg-RNA and eIF4F within the context of the 48S 
ribosomal initiation complex.  
Similar geometric constraints are likely to affect the 
translation initiation mechanisms of other genera within the 
Caliciviridae, even though their VPg proteins lack the 
eIF4G-binding motif found in norovirus VPg. For example, 
the best available evidence suggests that binding of FCV 
VPg to eIF4E is required for translation initiation [27,37]. 
This positions the FCV VPg at a different locus within the 
eIF4F complex compared to MNV VPg, though their 
binding sites on eIF4F may not be far apart – the eIF4E 
binding site in eIF4G (residues 557-681) is close to the 
HEAT-1 domain (residues 751-1011) [9]. Intriguingly, the 
mechanism reported here for noroviruses may also operate 
in rice yellow mottle virus (RYMV) since there is evidence 
to suggest that its VPg protein binds to the eIF4G HEAT-1 
domain [50] and appears to have a C-terminal sequence 
that is similar to the HEAT-1 binding motif identified in 
norovirus VPg (Fig 4A).   
The observation that the VPg-NS6pro fusion protein cannot 
bind to the eIF4G HEAT-1 domain (Fig 2D) shows that the 
C terminus of VPg has to be free for a productive 
interaction, and raises interesting questions about the 
regulation of norovirus replication. As with all positive-
sense, single-strand RNA viruses, the early stages of 
norovirus infection are dominated by translation, which 
allows the accumulation of copies of the polyprotein 
precursor. This precursor is eventually processed by NS6pro 
into the functional proteins required for virus replication. 
The precise timings of the processing cascade are not 
known in detail, although evidence suggests that cleavage 
of VPg-NS6pro is significantly slower than the early 
cleavages at the NS2-3 and NS3-4 sites [51,52]. It may 
well be that the timing of the processing of precursors 
containing VPg is tuned to permit an early burst of 
translation (unimpeded as long as VPg remains fused to 
NS6pro), followed by a switch to RNA replication that may 
be facilitated by the accumulation of free VPg (or 
precursors with VPg at the C terminus), which would bind 
to eIF4G and inhibit viral translation initiation. This might 
help to clear the viral RNA of ribosomes to facilitate 
initiation of RNA replication, which requires association of 
the viral NS7pol at the 3´-end followed by movement along 
the RNA template in the 3´-5´ direction. Consistent with this 
notion, we have shown that exogenous GST-VPg fusion 
proteins containing the eIF4G-binding peptide can inhibit 
translation from norovirus VPg-RNA (Fig 7A), but it remains 
to be seen if this hypothetical mechanism plays out in 
infected cells.  
Finally the discovery of a binding site on eIF4G that is 
critical for norovirus translation initiation raises the 
possibility that the VPg-eIF4G interaction might be targeted 
in the development of antiviral compounds. Our initial 
efforts to demonstrate the antiviral of VPg peptides failed to 
show any effect (Fig 8, Supplementary Fig S5), but this 
could simply be because an insufficient cytoplasmic 
concentration was achieved. In any case, small molecule 
inhibitors are likely to have improved pharmacokinetics and 
our results lay the necessary groundwork to enable high-
throughput screening for compounds that might disrupt the 
VPg-eIF4G interaction and so block infection.  
Materials and Methods 
Plasmids for protein expression in E. coli. Six different 
expression vectors were used to make new expression 
constructs. Briefly these were pETM-11 which has been 
described elsewhere [53]. Two modified versions of 
pETM-11, one with a BamHI site replacing the NcoI site 
(pETM-11m1), and the other, a variant of pETM-11m1, in 
which a thrombin cleavage site downstream of the N-
terminal His-tag replaces the Tobacco Etch Virus (TEV) NIa 
cleavage site (pETM-11m2) [54,55]. pMALX(E) has been 
described elsewhere [56] and pGEX-2T is commercially 
available (GE healthcare). An additional modified pGEX-2T 
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plasmid was used with a TEV NIa cleavage site replacing 
the thrombin site (pGEX-2Tm). eIF4GI, eIF4GII and DAP5 
sequences were amplified by PCR (KOD polymerase hot 
start kit) from full length cDNA clones.  
cDNA for eIF4GI, eIF4GII and DAP5 were kindly supplied 
by Chris Hellen and Tatyana Pestova (State University New 
York), Mark Coldwell (University of Southampton) and 
Bhushan Nagar (McGill University, Montréal) respectively. 
The residue numbering used throughout this paper for 
these proteins is based on the following NCBI accession 
codes, eIF4GI (AAM69365.1), eIF4GII (NP_003751.2) and 
DAP5 (NP_001036024.3). The oligonucleotide primers 
used in amplification of cDNA are given in Supplementary 
Table S1. Ligation into expression vectors was performed 
using the T4 Quick Ligation Kit (New England Biolabs).  
Fusions of glutathione-S-transferase (GST) with VPg C-
terminal peptide sequences were made by ligating 
annealed synthetic oligonucleotides into pGEX-2T 
(Supplementary Table S1). 5 µM of sense and anti-sense 
oligonucleotide were heated to 95°C for 12 minutes in NEB 
buffer 2 followed by slow cooling to room temperature over 
2.5 hours. The oligonucleotides were designed so that 
annealing would generate sticky ends corresponding to the 
BamHI and EcoRI restriction sites that were used in 
ligation.  
Green-fluorescent protein (GFP) fusions were made in the 
following way: cDNA for enhanced GFP-VPg and GFP-
VPg|NS6 fusions were generated by using overlap 
extension PCR to fuse enhanced GFP to MNV VPg 1-124 
using a ENLYFQGAAA linker between the two proteins that 
incorporates contains a TEV NIa Cleavage site 
(underlined). The PCR product was ligated into 
pETM-11m1.  
Full length hexa-Histidine-tagged VPg constructs (MNV 
VPg(1-124) wild-type (WT) and the F123A mutant, and 
FCV VPg(1-111) WT), and GST-eIF4GI 4GM (751-1132) 
constructs are described elsewhere [34,39]. pET15b-eIF4A 
was kindly supplied by Chris Hellen and Tatyana Pestova 
(State University New York) [57,58].  
Almost all mutations were made by QuikChange site 
directed mutagenesis (Stratagene). The exception to this 
was the MNV VPg(102-124) K120A mutant, which was 
made by annealing oligonucleotides and ligating the 
product as described above. Details of all of the constructs 
used in the study, including residue numbers, expression 
vector, purification tag details, protease cleavage site to 
remove the tag and non-native residues in the sequence 
post-cleavage are summarised in Supplementary Table S2. 
All constructs were verified by DNA sequencing (MWG 
Operon).  
Plasmids for protein expression in BV2 cells. Lentivirus 
vectors expressing mCherry-MNV1-VPg fusions were 
generated in two steps using the plasmid pTM900, a 
bicistronic lentiviral vector derived from 
pCCLsin.PPT.hPGK.GFP.pre that carries a multiple cloning 
site downstream of the human phosphoglycerate kinase 
promoter and coexpresses a hygromycin resistance gene 
under the control of the EMCV IRES [59,60]. The mCherry 
coding sequence lacking an in-frame stop codon was first 
amplified by PCR (see Supplementary Table 2 for primer 
details) and cloned into the lentiviral vector pTM900 
between the BshTI and BsiWI restriction to replace the 
open reading frame for green fluorescent protein (GFP). In 
the second step, the coding sequence of wild-type and 
mutated VPg peptides were inserted in frame with the 
mCherry ORF by hybridizing complementary single-
stranded oligonucleotides encoding the last 23 amino acids 
of MNV1 VPg flanked by BsiWI and XbaI restriction sites 
and ligated into the corresponding sites of the vector 
generated in the first step. The sequences of the 
oligonucleotides used to amplify MNV VPg wild-type and 
F123A mutants for cloning into the lentivirus vector are 
given in Supplementary Table S2. A bicistronic lentiviral 
vector co-expressing mCherry and a hygromycin 
resistance gene was used as negative control. All plasmid 
sequences were verified by DNA sequencing. 
Protein expression and purification. All proteins were 
expressed in E. coli BL21-CodonPlus(DE3) RIPL or BL21-
Rosetta(DE3) cells. The cells type used for each construct 
is given in Supplementary Table S3. For non-isotopically 
labelled proteins 1 L of lysogeny broth (LB) was seeded 
using 50 mL of an overnight starter culture. The cells were 
grown at 220 RPM and 37°C until mid-log phase was 
reached (OD600 of ~0.6-0.8) at which point the cells were 
typically induced with 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and allowed to grow at 220 
RPM and a defined temperature and period of time. Cells 
were pelleted by centrifugation at ~5,000 g and stored at 
-80°C. The temperature and time regimen used for each 
protein are listed in Supplementary Table S3.  
For expression of 15N labelled eIF4GI HEAT-1 four 1 L 
cultures of LB were seeded and grown to mid-log phase. At 
this point the cells were pelleted at ~3,000 g for 20 
minutes. The supernatant was discarded and the cells re-
suspended in 800 mL of sterile TBS (50 mM Tris pH 7.5, 
150 mM NaCl). The centrifugation step was repeated, the 
supernatant discarded and the pellets finally re-suspended 
in a total of 1 L of minimal medium divided between two 1 L 
culture flasks. The minimal medium, which contained 
15NH4Cl as a labelled nitrogen source, was prepared as 
detailed in Supplementary Table S4. Protein expression 
was induced after 2 hours at 30°C by addition of 1 mM final 
IPTG and continued for approximately 16 hours at 30°C 
and 220 RPM. The cells were harvested and stored as 
previously described.  
The purification of the various recombinant proteins from 
E. coli followed the general scheme presented below. The 
details of the buffers used for each protein purification are 
fully documented in Supplementary Table S5 (and cross-
referenced to the data presented in each figure); any 
significant deviations from the protocol below are given in 
the supplementary methods.  
Cells were re-suspended in a purification buffer (spiked 
with 2 mg/mL final Chicken egg lysozyme, 0.1 mM 
phenylmethanesulfonyl fluoride (PMSF) and 0.1% Triton 
X-100) and lysed by sonication in 15-second pulses 
separated by 15-second rests on ice over a period of 5 
minutes. Lysates were clarified by centrifugation at 
29,000 g for 20 minutes. DNA was precipitated by addition 
of protamine sulfate to a concentration of 1 mg/mL and the 
lysate centrifuged again at 29,000 g for 20 minutes. 
Clarified lysates were applied to their respective affinity 
resins: TALON (Clontech) or His-select (Sigma) for His-
tagged protein, Glutathione 4B (GE Healthcare) resin for 
GST tagged proteins, or amylose resin (New England 
Biolabs) for MBP-tagged proteins. In each case the lysate 
was slowly rotated with the resin for ~1 h at 4°C and then 
applied to a gravity flow column. The washing and elution 
strategy employed was dependent on the affinity strategy 
being employed. For His-tagged proteins the resin was 
washed sequentially with 25 mL batches of purification 
buffer with increasing concentrations of imidazole. Proteins 
typically eluted at an imidazole concentration of 100 mM. 
For GST-tagged proteins the resin was washed with four 
25 mL batches of purification buffer and eluted with two 
washes of the same buffer containing 10 mM reduced 
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glutathione, the first titrated to pH 8 the second to pH 9; 
MBPtagged proteins bound to the amylose resin were 
washed in the same way but the protein was eluted using 
15 mL of purification buffer containing 10 mM maltose. 
Pure fractions were dialysed overnight (14-17 hours) 
against 4 L of dialysis buffer (Supplementary Table S5). For 
proteins in which the affinity tag was removed this was 
done by addition of protease (typically 0.5 mg TEV NIa or 
200 U Bovine thrombin for 2 L cultures) at the beginning of 
dialysis. 
Following dialysis, proteins which had not been processed 
to remove tags were concentrated using centrifugal 
concentrator, snap frozen in liquid nitrogen and stored at 
80°C. Proteins that were proteolytically-processed during 
overnight dialysis were re-applied to the appropriate affinity 
resin to remove the cleaved tag. The flow-through fractions 
obtained at this stage, which contained the untagged 
protein, were concentrated in a centrifugal concentrator 
and further purified by size exclusion chromatography 
(SEC), typically using a Superdex 75 16/60 column 
connected to an ÄKTA FPLC (GE Healthcare). The SEC 
buffers are detailed in Supplementary Table S5. Pure 
fractions were pooled and concentrated using centrifugal 
concentrator and snap frozen in liquid N2 and stored at 
-80°C. Protein concentrations were determined from optical 
density measurements at 280 nm using calculated 
extinction coefficients; peptide concentrations were 
calculated from the dry weight of synthesised material. 
Glutathione affinity pull-down assays. These assays 
were performed to probe the binding of various glutathione-
S-transferase (GST) tagged eIF4G proteins (used as bait) 
to N-terminally His-tagged MNV VPg (1-124) (prey). In a 
typical experiment, 30 µL of the GST-eIF4G and MNV VPg 
proteins were mixed in SigmaPrep spin columns with 
430 µL of Tris binding buffer (50 mM Tris pH 7.6, 150 mM 
NaCl), and 75 µL bed volume of glutathione sepharose 4B 
resin (GE healthcare). For these assays final protein 
concentrations were 1.4 µM bait and 2.3 µM prey. The 
mixture was allowed to rotate slowly at 4°C for 60 minutes 
prior to collection of the flow through by centrifugation at 
100 g for 30 seconds. The resin was washed 3 times with 
750 µL of Tris binding buffer by centrifugation. The protein 
was eluted by incubating the resin for 2 minutes with 75 µL 
of Tris elution buffer (100 mM Tris pH 8, 300 mM NaCl, and 
10 mM reduced glutathione) prior to centrifugation at 
2,000 g for 2 minutes. Pre-purification mixtures and eluate 
samples were analysed by SDS PAGE and Coomassie 
staining. 
Cobalt affinity pull-down assays. These assays were 
usually performed using N-terminally His-tagged versions 
of FCV VPg 1-111 or MNV VPg 1-124 as bait and N-
terminally GST-tagged eIF4G constructs as the prey 
protein (see individual figures for details). Before use GST-
tagged prey proteins were dialysed overnight (at a volume 
ratio of 1/1000) into 25 mM 2-(N-morpholino)ethanesulfonic 
acid (MES) pH 6.5, 150 mM NaCl, 2 mM 
2mercaptoethanol. The VPg bait proteins were in a buffer 
containing 15.2 mM Na2HPO4, 34.2 mM NaH2PO4, pH6.5, 
300 mM NaCl and 1 mM DTT. For each assay typically a 
40 µL mixture of bait and prey proteins was added to 
450 µL of phosphate binding buffer (9.2 mM NaH2PO4,1.8 
mM KH2PO4, 136.9 mM NaCl, 2.7 mM KCl, 1 mM 
2mercaptoethanol, which was titrated to pH 7.4 with 
NaOH) in a SigmaPrep spin column along with 25 µL bed 
volume of TALON resin (Clontech). Typical final protein 
concentrations were 1 µM for the bait and 6 µM for the prey 
(see figure legends for details). The mixture was rotated 
slowly at 4°C for approximately 70 minutes. Following 
incubation the unbound fraction was collected by 
centrifugation of the spin columns at 100 g for 5 seconds. 
The resin was then washed by centrifugation, once with 
750 µL phosphate binding buffer, and then twice with 750 
µL binding buffer containing 10 mM imidazole. Bound 
proteins were eluted by incubating the resin for 2 minutes 
with 50 µL of phosphate binding buffer containing 250 mM 
imidazole, followed by centrifugation for 2 minutes at 
2,000 g. Samples of eluates and protein mixes taken 
before application to the resin analysed by SDS PAGE and 
Coomassie staining.  
Fluorescence anisotropy binding assays. Fluorescence 
anisotropy was used to measure the binding of synthetic 
VPg peptides (labelled at the N terminus with fluorescein 
isothiocyanate (FITC)) to HEAT-1 domains from eIF4G1, 
eIF4GII and DAP5. Measurements were performed at 29°C 
using a Spectramax i3 Spectrometer with excitation/
emission wavelengths of 485 and 535 nm respectively, slit 
widths set to 20 nm (excitation) and 25 nm (emission) and 
an integration time of 400 ms. Samples were loaded into 
non-binding surface black half area plates (Corning) using 
a MES binding buffer composed of 25 mM MES pH 6.5, 
150 mM NaCl, 3 mM DDT, 0.05% Tween-20.  
N-terminally FITC labelled peptides MNV VPg 104-124 
(VGPSWADDDRQVDYGEKINFE-COOH) and MNV VPg 
108-124 were purchased at >95% purity from 
ChinaPeptides Co., Ltd. (Shanghai, China). In both cases 
the FITC group was attached with via a 6-aminohexanoic 
acid group to the N terminus of the peptide. Peptides were 
dissolved in binding buffer and titrated to pH 6.5 using a 
small volume of concentrated NaOH. The final peptide 
concentration was kept at a constant 10 nM across all 
binding experiments. The proteins tested for binding – 
untagged eIF4GI HEAT-1 truncated (748-993), untagged 
eIF4GII HEAT-1 (745-1003), MBP tagged eIF4GII HEAT-1 
(745-1003) and DAP5 HEAT-1 (61-323) – were all 
dissolved in MES binding buffer. For each experiment a 
two-fold dilution series of each HEAT-1 protein was 
performed (typically starting at 20 or 40 µM) using MES 
binding buffer as diluent. For each dilution series, a no-
protein control was performed in which binding buffer 
replaced protein. Each measurement typically involved two 
independent dilution series performed in parallel. The 
average fluorescence anisotropy values for the no-protein 
controls were subtracted from the fluorescence anisotropy 
values for each point in the titration giving the difference 
(ΔFA) for each data point. The ΔFA values for each point in 
the titration were used to calculate the dissociation 
constant (KD) for each interaction tested. This was done by 
fitting all of the titration data to a single-site binding model 
(ΔFA = FAmax*[protein]/(KD + [protein]) where FAmax is the 
maximal change in fluorescence anisotrpy) in Prism6 
(GraphPad Software). 
Titration of up to 40 µM eIF4GI into an irrelevant peptide 
([FITC]-GSSHRYFLERGLESATSL; [61]) did not result in 
significant increases in fluorescence anisotropy (ΔFA < 
0.004), confirming the specificity of the interaction with the 
MNV VPg peptides. 
Isothermal Titration Calorimetry (ITC). For ITC 
experiments MNV VPg 1-124 and eIF4GII HEAT-1 
(745-1003) – both with their His-tags removed – were 
dialysed overnight into 1 L of MES binding buffer using 
Sigma-Pur-a-lyzer midi dialyser (3,500 kDa MWCO). 
Following dialysis the protein stock concentrations were 
determined by measurement of absorption at 280 nm to be 
52 µM MNV VPg(1-124) and 544 µM eIF4GII HEAT-1. ITC 
experiments were performed at 29°C using a MicroCal 
iTC200 instrument by injecting small volumes of eIF4GII 
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HEAT-1 in 200 µL MNV VPg(1-124) in the sample cell. A 
total of 20 injections were performed, the first of 0.5 µL 
followed by 19 injections of 2 µL. The first two injections 
were separated by 180 s; all subsequent injections were 
separated by 120 s. Integrated raw data analysis was 
performed using Origin9 software using the single-site 
binding model to determine the values of KD, ΔH, ΔS and 
stoichiometry (n). Binding measurements were performed 
in triplicate. In a control titration performed with buffer 
replacing eIF4GII HEAT-1, the heat evolved was constant 
and less than 0.4 kcal/mol. 
Nuclear Magnetic Resonance (NMR) experiments. NMR 
chemical shift mapping was used to map interactions made 
by MNV VPg with the HEAT-1 domain of eIF4GI. 
Experiments were performed using a Bruker Avance II 800 
mHz spectrometer at 298 K. Titration of MNV VPg 104-124 
peptide into a solution containing 15N labelled untagged 
eIF4GI HEAT-1 truncated (748-993) was monitored by 
recording 1H-15N transverse-relaxation optimized 
spectroscopy (TROSY) NMR spectra. MNV VPg(104-124) 
peptide (ChinaPeptides Co., Ltd. Shanghai, China) was 
dissolved in 50 mM MES pH 6.5, 150 mM NaCl, 5 mM 2-
mercaptoethanol and titrated to pH 6.5 using a very small 
volume of 10 M NaOH. The reference  1H-15N TROSY 
spectrum was recorded from a 450 µL sample of 15N 
eIF4GI HEAT-1 protein at 212 µM dissolved in the same 
buffer containing 5% D2O used as a lock signal. The effects 
of peptide titration were measured at peptide:protein molar 
ratios of 0.117, 0.352, 0.587, 0.936, and 1.404 by 
sequential addition of 1.83 µL of peptide stock solution (6.1 
mM). The number of scans recorded in each 1H-15N 
TROSY NMR spectra were as follows, reference (16), 
0.117 (24), 0.352 (28), 0.587 (56), 0.936 (56), 1.404 (180). 
The data were transformed using NMRpipe and analysed 
using NMRview (One Moon Scientific) [62]. The deposited 
1H-15N assignments for eIF4GI HEAT-1 truncated 748-993 
(BMRB Entry 18738) was used to analyse the titration [43]. 
For peak volume analysis the peak list was adjusted to 
account for slight spectral changes. In addition, clearly 
overlapped peaks were deleted from the list. The eVolume 
function of NMRview was used to determine non-
overlapped peak volumes.  
Size exclusion chromatography with multi-angle light 
scattering (SEC-MALLS). To test for the formation of a 
ternary complex, untagged eIF4A 1-406, untagged MNV 
VPg 1-124 and N-terminally His-tagged eIF4GI HEAT-1 
truncated (748-993) were mixed together in a total volume 
of 210 µL with final concentrations of 117 µM, 110 µM, and 
132 µM of eIF4A, eIF4G and MNV VPg respectively. The 
mix was rotated slowly at room temperature for 30 minutes 
and then concentrated in an Amicon Ultra 500 10,000 
MWCO concentrator to 130 µL. This sample was injected 
onto a S200 10/300 GL column at 0.5 mL/min using a 1260 
Infinity HPLC system (Agilent Technologies). Light 
scattering and refractive index were measured using in-line 
miniDAWN TREOS and Optilab T-rEX detectors (Wyatt 
Technology).  
Binary complexes (eIF4A:eIF4GI HEAT-1 and MNV VPg:
4GI HEAT-1) and individual protein samples were prepared 
the same way with the exception that matched buffer 
replaced one or more of the protein components in the mix. 
SEC MALS data were analysed by Astra 6 software (Wyatt 
Technology) using a dn/dc value of 0.185 and weight-
averaged molar masses are reported. Peak protein 
fractions were also analysed by SDS PAGE and 
Coomassie staining.  
In vitro translation assays. MNV1 VPg-linked RNA was 
isolated from infected RAW 264.7 cells as described 
previously [27]. For these assays we used capped 
bicistronic constructs that contain an upstream 
chloramphenicol acetyl transferase (CAT) open reading 
frame (ORF) separated from a downstream luciferase 
(LUC) ORF by the IRES from either porcine teschovirus 
(PTV) or FMDV, which have been described previously 
[27]. In vitro translation was performed using the Flexi 
rabbit reticulocyte lysate system (Promega) in the presence 
of 35S-labelled methionine (EasyTag, Perkin Elmer). 
Translation reactions were performed essentially according 
to the manufacturer's protocol but scaled down to 12.5 µL 
and with the inclusion of 100mM KCl. They were pre-
incubated for 15 minutes with 3.5-28 µM purified protein 
GST-MNV VPg(102-124) (wild-type or F123A mutant) and 
then initiated by addition of either 25 ng/µL in vitro 
transcribed bicistronic RNA or 16 ng/µL MNV1 VPg-linked 
RNA to give a final reaction volumes of 12.5 µL. The 
reactions were incubated at 30°C for 90 min and 
terminated by addition of an equal volume of Tris buffer 
containing 10 mM ethylenediaminetetraacetic acid (EDTA) 
and 100 ng/mL RNase A. Translated proteins were re-
suspended in SDS PAGE sample buffer and resolved on a 
12.5 % polyacrylamide gel. Protein synthesis levels were 
quantified by autoradiography. The intensity of each band 
was quantified with reference to the value obtained in the 
absence of recombinant protein. 
Lentivirus vector particle production and transduction. 
Lentivirus vectors were used to test intracellular effects of 
MNV VPg peptide sequences expressed as C-terminal 
fusions with the fluorescent mCherry protein tag (see 
above). Vesicular stomatitis virus G-protein-pseudotyped 
lentiviral particles were generated by transient transfection 
of 293T cells grown in 6-wells plates using 1.25 µg lentiviral 
vector, 0.63 µg pMDLg/pRRE (Addgene #12251), 0.31 µg 
pRSV-Rev (Addgene#12253) and 0.38 µg pMD2.G 
(Addgene#12259) per well using published protocols [63]. 
Parental BV2 cells were transduced with lentiviral 
supernatants and incubated for 48 h. Transduced cells 
were then selected on the basis of their resistance to 
Hygromycin B at a concentration of 200 µg/mL and sub-
cultured for three additional passages. Cell populations 
expressing equal level of mCherry fluorescence were then 
enriched by FACS prior to infection with MNV1 or 
immunoprecipitation of mCherry-VPg protein (see below). 
Co-immunoprecipitation experiments with mCherry-
VPg. Approximately 107 BV2 transduced cells were 
washed with cold phosphate-buffered saline (PBS) and 
harvested in 200 µL lysis buffer (Tris-HCl 10 mM pH 7.5, 
NaCl 150 mM, NP40 0.5 %, EDTA 0.5 mM, PMSF 1 mM 
and 1x protease inhibitors (Calbiochem)). Cells were 
disrupted by up and down pipetting and lysates were 
centrifuged at 12,000 g for 10 min at 4°C. Clarified 
supernatants were diluted to 500 µL with lysis buffer. RFP-
Trap®_A agarose beads (Chromotek GmbH, Cat No: 
RTA-20) were added and the lysates were incubated for 
2 h at 4°C under gentle agitation. The beads were washed 
5 times with lysis buffer and proteins were eluted with 
Laemmli sample buffer. Immunoprecipitated proteins were 
detected using SDS PAGE and immunoblot analysis. As a 
control of protein expression in cells used for co-
immunoprecipitation experiments, total cell lysate 
corresponding to 5 % of the input used for 
immunoprecipitation was also analysed by immunoblot. 
Antibodies used were obtained from a variety of sources. 
Mouse monoclonal anti-eIF4E (A-10) (Cat No: sc-271480), 
rabbit polyclonal anti-eIF4G (H-300) (4GI) (cat No: 
sc-11373) and goat polyclonal anti-eIF4AI (N-19) (Cat No: 
sc-14211) were obtained from Santa Cruz Biotechnology 
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Inc. Rabbit polyclonal anti-eIF3D was obtained from 
ProteinTech (Cat No: 10219-1-AP). Mouse monoclonal 
anti-GAPDH was obtained from Ambion (Cat No: AM4300). 
Rat monoclonal anti-RFP (clone 5F8) was obtained from 
Chromotek GmbH. Rabbit polyclonal anti-PABP1 was 
obtained from Cell Signaling Technology (Cat No: #4992). 
Measurement of viral replication. The effect of excess 
added MNV VPg peptide sequences on MNV replication 
was tested using cell-penetrating peptides and ectopic 
expression of mCherry VPg.  
We used synthetic FITC-labelled peptides containing cell-
penetrating sequences from Bac7 or human 
Immunodeficiency Virus (HIV) TAT fused to residues 
102-124 of MNV VPg (sourced from ChinaPeptides Co. 
Ltd., Shanghai, China). F123A mutant variants of both 
peptides (which bind much less well to eIF4G) were also 
used. The peptide sequences were as follows: Bac-WT: 
FITC-PRPLPFPRPGNVVGPSWADDDRQVDYGEKINFE; 
Bac-F123A: FITC-
PRPLPFPRPGNVVGPSWADDDRQVDYGEKINAE; TAT-
WT: FITC-
GRKKRRQRRRPQNVVGPSWADDDRQVDYGEKINFE; 
TAT-F123A: FITC-
GRKKRRQRRRPQNVVGPSWADDDRQVDYGEKINAE. 
The identity and purity (>95%) of the labelled peptides 
were assessed by mass spectrometry and reverse-phase 
liquid chromatography. All peptides were dissolved in 
dimethyl sulfoxide (DMSO) at a concentration of 10 mM 
and stored at 80°C.  
Naïve BV2 cells were treated with peptides at a 
concentration of 100 µM in culture complete medium for 
150 min before being infected with MNV1 at low MOI (0.01 
TCID50 units/cell) in the presence of peptides. Untreated 
cells were cultured in the same conditions using DMSO. 
After the indicated period of time, total cell RNA was 
extracted using a GenElute Mammalian Total RNA 
Miniprep kit (Sigma) and normalised to a standard 
concentration before being reverse transcribed using 
random hexamers and MuMLV RT enzyme (Promega). 
SYBR green-based quantitative PCR was performed using 
MNV1-specific primers (Supplementary Table S2). Each 
sample was measured in biological triplicate and compared 
to a standard curve. Additional non-template and non-
reverse transcriptase samples were analysed as negative 
controls. Data were collected using a ViiA 7 Real-Time 
PCR System (Applied Biosystems). 
Measurements of viral replication in BV2 cells ectopically 
expressing mCherry-VPg fusion proteins or mCherry alone 
(prepared by lentiviral transduction as described above) 
were performed using a similar experimental setup.  
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Supplementary Figures 
Supplementary Figure 1: Amino acid sequence alignments of representative sequences for VPg of all 6 genogroups 
of Norovirus (GI-GIV). The representative strains used in the alignments are GI Hu/GI/Norwalk/1968/US, (NCBI accession 
AAC64602), GII Lordsdale virus Hu/GII/Lordsdale/1993/UK (NCBI accession P54634), GIII Bo/GIII/B309/2003/BEL (NCBI 
accession ACJ04905.1),Hu/GIV.1/LakeMacquarie/NSW268O (NCBI accession number AFJ21375), Mu/NoV/GV/MNV1/2002/
USA (NCBI accession ABU55564.1), GVI dog/GVI.1/HKU_Ca035F/2007/HKG (NCBI accession FJ692501). Sequence 
alignment was performed by ClustalW [64] and BioEdit (http://www.mbio.ncsu.edu/BioEdit/bioedit.html). 
  
Supplementary Figure 2: Comparison of binding of eIF4GII HEAT-1 and MBP-eIF4GII HEAT-1 to MNV VPg C-terminal 
peptides. FITC-labelled MNV VPg(104-124) and MNV VPg(108-124) peptides were used in fluorescence anisotropy binding 
assays with the HEAT-1 domain of eIF4GII (751-1009) in order to determine the KD of the interaction. ΔFP, the normalised 
change in fluoresce anisotropy (relative to a no protein control) is plotted against protein concentration. Where appropriate 
(N>1), error bars indicate the standard deviation in the mean ΔFP value observed. The assays were performed with 
untagged eIF4GII HEAT-1 (black) and an MBP-tagged version (purple). The data generated using the untagged protein were 
fit using GraphPad Prism to a single-site binding model. Solid line: MNV VPg(104-124); dashed line - MNV VPg(108-124). 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Supplementary Figure 3: NMR analysis of binding of MNV VPg(104-124) to eIF4GI. 1H-15N TROSY HSQC spectra 
obtained on titration of unlabelled MNV VPg(104-124) into 212 µM 15N-labelled eIF4GI HEAT-1 (748-993). (A) Reference 
spectrum obtained in the absence of MNV VPg(104-124). (B-F) Spectra obtained in the presence of (B) 0.12, (C) 0.35, (D) 
0.57, (D) 0.94 and (F) 1.35 molar equivalents of MNV VPg(104-124) peptide superposed on the reference spectrum. The 
molar equivalents of MNV VPg(104-124) peptide and the number of scans used to obtain the spectrum (which was increased 
as the average signal intensity decreased) each point in the titration. 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Supplementary Figure 4: GST-MNV VPg(102-124) does not inhibit cap-dependent or PTV IRES-dependent translation. 
In vitro translation reactions were performed in the presence of increasing concentrations of GST-MNV VPg(102-124) WT 
protein or the GST-MNV VPg(102-124) F123A mutant that binds much less well eIF4G. Protein synthesis was monitored by 
autoradiography of SDS PAGE analysis of incorporation of 35S-methionine in translation reactions. Top panel: Effect of 
exogenous GST-MNV VPg(102-124) proteins on translation from capped bi-cistronic mRNA constructs containing the PTV 
IRES between the first (CAT) and second (Luc) cistrons; bottom panel: quantitative analysis of the level of 35S-methionine 
incorporation. 
 
Supplementary Figure 5: Cell penetrating FITC-Bac7-MNV VPg(102-124) peptides do not inhibit MNV infection of BV2 
cells.  (A) Fluorescence microscopy analysis of cell penetration of the FITC-Bac7-MNV VPg 102-124 peptides. The images 
shown are merged images of DAPI stained nuclear DNA (blue) and wild-type or F123A versions of the cell penetrating 
peptides (green). (B) Time course of BV2 infection (MOI 0.01 TCID50 units/cell) with MNV1 following pre-treatment for 150 
minutes with 100 µM of wild-type or F123A versions of the cell penetrating peptides prior to infection. The progress of 
infection was monitored by RT-PCR analysis (as in Fig 8). 
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Supplementary Materials and Methods – Specific adjustments to purification protocols  
MNV VPg 1-124 WT and mutants used in mutational mapping of the eIF4G-VPg interaction. 
Six of the hexa-His-tagged MNV VPg 1-124 protein constructs (wild-type, F123A, 120KIN→120ESA, 116DYGE→116RAPK, 
112DRQV→112REAS, and 108WADD→108APRR) used to delineate the extent of the eIF4GI binding site in cobalt affinity pull-
down assays (presented in Fig 2B) were initially purified on TALON resin essentially as described in Materials and Methods. 
However, following overnight dialysis in 50 mM HEPES pH 7.3, 300 mM NaCl, 2 mM 2-mercaptoethanol, two of the mutant 
proteins – 116DYGE→116RAPK and 108WADD→108APRR  – were found to have OD260/280 ratios of 1.51 and 1.95 
respectively. These were unusually high and suggested significant nucleic acid contamination. In order to remove any bound 
nucleic acids the proteins were diluted approximately ten-fold with phosphate buffer (15.8 mM Na2HPO4, 34.2 mM NaH2PO4, 
pH 6.5, 300 mM NaCl, 1 mM DTT) and protamine sulfate was added to a concentration of 1 mg/mL. Precipitated nucleic 
acids were removed by centrifugation at 29,000g for 20 minutes. The protein in the supernatant was then rebound to TALON 
cobalt resin (Clontech) for 1 h with slow rotation, after which the slurry was applied to a gravity flow column and the resin 
washed with 75 mL of phosphate buffer. The protein was eluted with 10 mL of phosphate buffer supplemented with 100 mM 
imidazole. Eluted fractions were dialysed for 13 hours against 4 L phosphate buffer and the proteins concentrated and frozen 
as described in the Material and Methods section.  
The MNV VPg 104VGPS!104KKAH mutant and 103GSGSGS purifications were modified based on the purifications of the 
other mutants. These were purified as per the Materials and Methods. 50 mM sodium phosphate pH 6.5 (15.8 mM Na2HPO4, 
34.2 mM NaH2PO4), 300 mM NaCl, 1 mM DTT was used as the buffer for both purification buffer and dialysis.  
The final A260/280 of the WT and all the mutant MNV VPg 1-124 proteins was 0.61 or less. 
eIF4GI HEAT-1 truncated (748-993) wild-type and mutants used in mutational mapping of the eIF4G-VPg interaction. 
The wild-type and mutant eIF4GI HEAT-1 (748-993) proteins were initially purified, to completion, as described in Materials 
and Methods. However the high OD260/280 ratio of some of the mutant proteins was suggestive of nucleic acid 
contamination (D919R – 1.6, L939A – 1.04, H918A – 1.145, K901M-E914R – 1.15, L897A – 0.84). Therefore the purified 
proteins were thawed and incubated with 1 µM MgCl2 and 387 U benzonase nuclease (Sigma) for 70-90 minutes (typically 1 
U benzonase per 0.02 mg protein). The mixture was then subjected to size-exclusion chromatography on a Superdex 75 
10/300 GL column equilibrated with 10.1 mM Na2HPO4, 1.8 mM KH2PO4 , pH 7.2, 136.9 mM NaCl, 2.7 mM KCl, and 1 mM 
tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl). Peak fractions were pooled, concentrated and stored frozen. The 
final OD260/280 ratios were all under 0.7. 
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Supplementary,Table,1,0,Construct,Details
Numbering NCBI accession Vector Purification tag 1 Purification tag 2 Protease cleave juntion for tag 1 removal Non-native residues post-tag 1 removal Figures
MNV VPg  WT and mutants 1"124 DQ285629.1 pETM-11 N-terminal hexa histidine TEV Nia GAM 1B 1C 2A 2C 3C 5D"E 6A"B
MNV VPg 1"85 DQ285629.1 pETM-11 N-terminal hexa histidine TEV Nia GAM 2A
FCV VPg 1"111 AY560114.1 pETM-11 N-terminal hexa histidine TEV NIa G 1C
GST-MNV VPg C-term WT and mutants 102"124 DQ285629.1 pGEX-2T N-terminal GST Thrombin Never removed tag 4B 4C 4D 7A"B S4
GST-Lordsdale-GII VPg C-term 111"133 P54634.1 pGEX-2T N-terminal GST Thrombin Never removed tag 4B
GST-Norwalk-GI VPg C-term 116"138 AAC64602.1 pGEX-2T N-terminal GST Thrombin Never removed tag 4B
GST-B309-GIII VPg C-term 93"115 AC304905.1 pGEX-2T N-terminal GST Thrombin Never removed tag 4B
GST-FCV-F9 VPg C-term 87"111 AAT66080.1 pGEX-2T N-terminal GST Thrombin Never removed tag 4B
GST-HuASt4 VPg  C-term 73"91 Q3ZN06.2 pGEX-2T N-terminal GST Thrombin Never removed tag 4B
GFP-MNV-GV VPg WT and F123A 1"124 DQ285629.1 pETM-11-mod1* N-terminal hexa histidine N-terminal GFP TEV Nia Never removed tag 2D
GFP-VPg|NS6 fusion C139A 1"307 DQ285629.1 pETM-11-mod1* N-terminal hexa histidine N-terminal GFP TEV Nia Never removed tag 2D
eIF4GII HEAT-1 745"1003 NP_003751.2 pMALX(E) N-termianl MBP - - S2
eIF4GII HEAT-1 745"1003 NP_003751.2 pETM-11-mod1* N-terminal hexa histidine TEV Nia GS 2D 3A 3C
eIF4GI HEAT-1 751"1010 AAM69365.1 pETM-11-mod2** N-terminal hexa histidine Thrombin Never removed tag 4B 4C 4D
eIF4GI HEAT-1 trunacted WT and mutants 748"993 AAM69365.1 pETM-11-mod1* N-terminal hexa histidine TEV Nia GS 3A 5A"E 6A"B
GST-eIF4GI HEAT-1 751"1010 AAM69365.1 pGEX-2T_mod1‡ N-terminal GST TEV Nia Never removed tag 1C 2C
GST-eIF4GII HEAT-1 745"1003 NP_003751.2 pGEX-2T_mod1‡ N-terminal GST TEV Nia Never removed tag 2C
GST-eIF4GI 4GM 652"1132 AAM69365.1 pGEX-2T_mod1‡ N-terminal GST TEV Nia Never removed tag 1B 1C
GST-eIF4GI 652-751-C-term_his 652"750 AAM69365.1 pGEX-2T_mod1‡ N-terminal GST C-terminal hexa histidine TEV Nia Never removed tag 1B
GST-eIF4GI 1011-1132-C-term_his 1011"1132 AAM69365.1 pGEX-2T_mod1‡ N-terminal GST C-terminal hexa histidine TEV Nia Never removed tag 1B
GST-eIF4GI HEAT-1-C-term_his 751"1010 AAM69365.1 pGEX-2T_mod1‡ N-terminal GST C-terminal hexa histidine TEV Nia Never removed tag 1B 2A
DAP5 HEAT-1 61"323 NP_001409 pETM-11-mod1* N-terminal hexa histidine TEV Nia GS 3B
eIF4AI 1"406 NP_001407 pET15B_mod‡‡ N-terminal hexa histidine Thrombin GSHMLEDPFLRI 6A"B
GST pGEX-2T 1B 1C 2C
* BamHI engineered to replace NcoI site at the 5' linker site of pETM-11 * BamHI engineered to replace NcoI site at the 5' linker site of pETM-11
** Thrombin engineered into replace the TEV Nia site in Mod_pETM-11_1 ** Thrombin engineered into replace the TEV Nia site in Mod_pETM-11_1
‡ TEV Nia site engineered to replace the thrombin site of pGEX-2T ‡ TEV Nia site engineered to replace the thrombin site of pGEX-2T
‡‡ Described in Pestova et al., 1996, and Pisarev et al., 2007 ‡‡ Described in Pestova et al., 1996, and Pisarev et al., 2007
Supplementary,Table,2,0,Primers
Oligonucleotides - PCR amplifation for liagation:
Target Vector Target sequence for ligation Sequence 5′ - 3′ Materials and Methods section
Mod_pETM11_1* and pGEX2T_mod‡ DAP5 HEAT-1 (61-323) F catcatGGATCCAACTCCGCAGCAAACAACTCC Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1* and pGEX2T_mod‡ DAP5 HEAT-1 (61-323) R catcatGAATTCttaGATCGTCTTTGGTCCATTGTC Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T_mod eIF4GII HEAT-1 (751-1009) F CATCATGGATCCGATCCCGAAAACATTAAAACC Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T_mod eIF4GII HEAT-1 (751-1009) R CATCATGAATTCTCAagcctctttgtgaatctgttc Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T_mod eIF4GI 4GM (751-1132) F CATCATGGATCCctggaccccactagactacaa Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T_mod eIF4GI 4GM (751-1132) R CATCATGAATTCTCAgggtaccgcttgttgaagggc Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T_mod eIF4GI HEAT-1 (751-1010) F CATCATGGATCCgaagatgctgatggcagcaaa Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T_mod eIF4GI HEAT-1 (751-1010) R CATCATGAATTCTCAagcctccttatggatctggtc Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993)F catcatgaattctcatggcacccaattgctccctcgcagatc Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993)R catcatggatcccgaggggaagaagatgctgat Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_2** eIF4GI HEAT-1 (751-1010) F CATCATGGATCCGAAGATGCTGATGGCAGCAAA Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_2** eIF4GI HEAT-1 (751-1010) R CATCATAAGCTTATCAAGCCTCCTTATGGATCTGGTC Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GII HEAT-1 (751-1009) F CATCATGGATCCGATCCCGAAAACATTAAAACC Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GII HEAT-1 (751-1009) R CATCATGAATTCTCAagcctctttgtgaatctgttc Plasmids(for(protein(expression(in!E.!coli.(
pMALX_E eIF4GII HEAT-1 (751-1009)F catcatgcggccgcagatcccgaaaacattaaaaccc Plasmids(for(protein(expression(in!E.!coli.(
pMALX_E eIF4GII HEAT-1 (751-1009)R catcataagctttcaagcctctttgtgaatctgttcg Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T_mod eIF4GI 1011 F catcatggatccgagatggaagaacatcgagag Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T_mod eIF4GI 1132 C-term his R catcatgaattctcaGtgatggtgatggtgatggggtaccgcttgttgaagggc Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T_mod eIF4GI 751 C-term His R catcatgaattcttaGtgatggtgatggtgatgttcccctcgatccttatcagccgc Plasmids(for(protein(expression(in(BV2(cells
pTM900 mCherry F AAAAaccggtgccaccATGGTGAGCAAGGGCGAGGAGG Plasmids(for(protein(expression(in(BV2(cells
pTM900 mCherry R AAAAcgtacgCTTGTACAGCTCGTCCATGCCGC
Oligonucleotides - Overlap extension PCR amplification for eGFP-VPg fusion ligation 
Target Vector Overlap extension cloning of GFP fusions Sequence 5′ - 3′ 
Mod_pETM11_1*  OE_5ʹ_eGFP_F CATCATGGATCCATGGTGAGCAAGGGCGAGGAGCTGTTCACC 
Mod_pETM11_1*  OE_overlap_R TGCGGCCGCTCCCTGAAAATAAAGATTCTCCTTGTACAGCTCGTCCATGCCGAGAGT 
Mod_pETM11_1*  OE_overlap_F GAGAATCTTTATTTTCAGGGAGCGGCCGCAGGAAAGAAGGGCAAGAACAAGAAG 
Mod_pETM11_1*  OE MNV VPg 124 Rev catcatCTCGAGttactcaaagttgatcttctcgccgtagtcgacctG
Mod_pETM11_1*  OE MNV VPg 124 Rev F123A catcatCTCGAGttactccgcgttgatcttctcgccgtagtcgacctG
Mod_pETM11_1*  OE_3ʹ_NS6 Rev CATCATAAGCTTACTGGAACTCCAGAGCCTC
Oligonucleotides - Annealing and direct liagation:
Target Vector Target sequence for annealing and direct ligation Sequence 5′ - 3′ 
pGEX2T GST-MNV (GV) VPg 102-124 sense GATCCaacgtagtgggtcCaagttgggcagacgatgacCGTcaagttgattatggagaaaaaattaattttgagTGAG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-MNV (GV) VPg 102-124 anti-sense AATTCTCACTCAAAATTAATTTTTTCTCCATAATCAACTTGACGGTCATCGTCTGCCCAACTTGGACCCACTACGTTG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-NV VPg (GI) 116-138 sense GATCCACTCCACCAAAAAACGAATGGGCAGACGATGACCGTGAAGTAGATTATACAGAGAAAATTAATTTTGAGTGAG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-NV VPg (GI)116-138 anti-sense AATTCTCACTCAAAATTAATTTTCTCTGTATAATCTACTTCACGGTCATCGTCTGCCCATTCGTTTTTTGGTGGAGTG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-LDV VPg (GII) 111-133 sense GATCCaaaccaaaaggaaaattgtgggcagatgacgatcgtagtgtagactataatgagaaattaGattttgaaTGAG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-LDV VPg (GII) 111-133 anti-sense AATTCTCATTCAAAATCTAATTTCTCATTATAGTCTACACTACGATCGTCATCTGCCCACAATTTTCCTTTTGGTTTG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-BoNV VPg (GIII) 87-109 sense GATCCaatccagttggaccaagttgggcagatgacgagcgtgaagtggattataacgaggtaattgaatttcaaTGAG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-BoNV VPg (GIII) 87-109 anti-sense AATTCTCATTGAAATTCAATTACCTCGTTATAATCCACTTCACGCTCGTCATCTGCCCAACTTGGTCCAACTGGATTG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-FCV VPg 87-111 sense GATCCGTTAAACATGAAAAAATTCGTACAAATACTTTAAAAGCAGTAGATCGTGGATATGACGTGAGTTTTGCAGAGGAATGAG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-FCV VPg 87-111 anti-sense AATTCTCATTCCTCTGCAAAACTCACGTCATATCCACGATCTACTGCTTTTAAAGTATTTGTACGAATTTTTTCATGTTTAACG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-HuASt4 VPg 75-93 sense GATCCGGTGTTGTAGGAGACGATGTAGAATTTGATTATACAGAGGTGATTAATTTTGACCAATGAG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-HuASt4 VPg 75-93 sense AATTCTCATTGGTCAAAATTAATCACCTCTGTATAATCAAATTCTACATCGTCTCCTACAACACCG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-MNV_VPg_102-124_K120A sense GATCCAACGTAGTGGGTCCAAGTTGGGCAGACGATGACCGTCAAGTTGATTATGGAGAAgcAATTAATTTTGAGTGAG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-MNV_VPg_102-124_K120A anti-sense AATTCTCACTCAAAATTAATTgcTTCTCCATAATCAACTTGACGGTCATCGTCTGCCCAACTTGGACCCACTACGTTG Plasmids(for(protein(expression(in!E.!coli.(
pTM900 (mCherry inserted as per M&Ms) mCherry-MNV1-VPg-WT sense GTACGAATGTGGTTGGCCCCTCCTGGGCTGACGATGACCGCCAGGTCGACTACGGCGAGAAGATCAACTTTGAGTAAT Plasmids(for(protein(expression(in(BV2(cells
pTM900 (mCherry inserted as per M&Ms) mCherry-MNV1-VPg-WT anti-sense CTAGATTACTCAAAGTTGATCTTCTCGCCGTAGTCGACCTGGCGGTCATCGTCAGCCCAGGAGGGGCCAACCACATTC Plasmids(for(protein(expression(in(BV2(cells
pTM900 (mCherry inserted as per M&Ms) mCherry-MNV1-VPg-F123A sense GTACGAATGTGGTTGGCCCCTCCTGGGCTGACGATGACCGCCAGGTCGACTACGGCGAGAAGATCAACgctGAGTAAT Plasmids(for(protein(expression(in(BV2(cells
pTM900 (mCherry inserted as per M&Ms) mCherry-MNV1-VPg-F123A anti-sense CTAGATTACTCagcGTTGATCTTCTCGCCGTAGTCGACCTGGCGGTCATCGTCAGCCCAGGAGGGGCCAACCACATTC Plasmids(for(protein(expression(in(BV2(cells
Oligonucleotides - Annealing and direct liagation:
Target vector QuikChange PCR Sequence 5′ - 3′ Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 K771A F agggtgcgctccatcctgaatgcactgacaccccagatgttccag Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 K771A R ctggaacatctggggtgtcagtgcattcaggatggagcgcaccct Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 E914R F ttgttcaagcttaagatgttaacacgcgcaataatgcatgactgtgtg Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 E914R R cacacagtcatgcattattgcgcgtgttaacatcttaagcttgaacaa Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 L939A F tgatgaagagtccctcgagtgcctttgtcgtgcgctcaccaccattggcaaagac Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 L939A R gtctttgccaatggtggtgagcgcacgacaaaggcactcgagggactcttcatca Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 D919R F atgttaacagaggcaataatgcatcgctgtgtggtcaagcttcttaagaaccatgatgaagag Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 D919R R ctcttcatcatggttcttaagaagcttgaccacacagcgatgcattattgcctctgttaacat Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 H918A F atgttaacagaggcaataatggctgactgtgtggtcaagcttcttaagaaccatgatgaagag Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 H918A R ctcttcatcatggttcttaagaagcttgaccacacagtcagccattattgcctctgttaacat Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 L912A F ttgttcaagcttaagatggcaacagaggcaataatgcatgac Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 L912A R gtcatgcattattgcctctgttgccatcttaagcttgaacaa Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 L897A F gacatagcccggcggcgctctgcagggaatatcaagtttattgga Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1*  eIF4GI HEAT-1 truncated (748-993) eIF4GI HEAT-1 L897A R tccaataaacttgatattccctgcagagcgccgccgggctatgtc Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1* MNV VPg|NS6 1-307 MNV NS6 C139A F CTCGGGACCATCCCAGGCGACGCAGGCTGTCCCTATGTTTATAAG Plasmids(for(protein(expression(in!E.!coli.(
Mod_pETM11_1* MNV VPg|NS6 1-307 MNV NS6 C139A R CTTATAAACATAGGGACAGCCTGCGTCGCCTGGGATGGTCCCGAG Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 103 GSGSGS F Aagccgatcgactggaatgtgggatccggcagcggcagcgttggcccctcctgggctgac Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 103 GSGSGS R gtcagcccaggaggggccaacgctgccgctgccggatcccacattccagtcgatcggctT Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 104 VGPS → KKAH F Aagccgatcgactggaatgtgaaaaaagcccattgggctgacgatgaccgccag Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 104 VGPS → KKAH R ctggcggtcatcgtcagcccaatgggcttttttcacattccagtcgatcggctT Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 108 WADD → APRR F Tggaatgtggttggcccctccgccccgcgtcgtgaccgccaggtcgactacggc Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 108 WADD → APRR R gccgtagtcgacctggcggtcacgacgcggggcggaggggccaaccacattccA Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 112 DRQV → REAS F Ggcccctcctgggctgacgatcgtgaagcttctgactacggcgagaagatcaac Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 112 DRQV → REAS R gttgatcttctcgccgtagtcagaagcttcacgatcgtcagcccaggaggggcC Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 116 DYGE → RAPK F Tgggctgacgatgaccgccaggtccgtgccccgaaaaagatcaactttgagtaaactt Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 116 DYGE → RAPK R aagtttactcaaagttgatctttttcggggcacggacctggcggtcatcgtcagccca Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 120 KIN → ESA F gaccgccaggtcgactacggcgaagaatctgcctttgagtaaacttgtcgac Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 120 KIN → ESA R Gtcgacaagtttactcaaaggcagattcttcgccgtagtcgacctggcggtc Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 F123A F cggcgagaagatcaacgctgagtaagattcatggcg Plasmids(for(protein(expression(in!E.!coli.(
pETM11 MNV VPg 1-124 MNV VPg 1-124 F123A R cgccatgaatcttactcagcgttgatcttctcgccg Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T MNV (GV) VPg 102-124 GST-MNV VPg 102-124 D110A,D111A F GTGGGTCCAAGTTGGGCAGCGGCGGACCGTCAAGTTGATTATGGA Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T MNV (GV) VPg 102-124 GST-MNV VPg 102-124 D110A,D111A R TCCATAATCAACTTGACGGTCCGCCGCTGCCCAACTTGGACCCAC Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T MNV (GV) VPg 102-124 GST-MNV VPg 102-124 W108A F AACGTAGTGGGTCCAAGTGCGGCAGACGATGACCGTCAA Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T MNV (GV) VPg 102-124 GST-MNV VPg 102-124 W108A R TTGACGGTCATCGTCTGCCGCACTTGGACCCACTACGTT Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T MNV (GV) VPg 102-124 GST-MNV VPg 102-124 V115A F GCAGACGATGACCGTCAAGCGGATTATGGAGAAAAAATT Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T MNV (GV) VPg 102-124 GST-MNV VPg 102-124 V115A F AATTTTTTCTCCATAATCCGCTTGACGGTCATCGTCTGC Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T MNV (GV) VPg 102-124 GST-MNV VPg 102-124 D110A F GTAGTGGGTCCAAGTTGGGCAGcgGATGACCGTCAAGTTGATTAT Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T MNV (GV) VPg 102-124 GST-MNV VPg 102-124 D110A R ATAATCAACTTGACGGTCATCcgCTGCCCAACTTGGACCCACTAC Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T MNV (GV) VPg 102-124 GST-MNV VPg 102-124 R113A F ccaagttgggcagacgatgacgcgcaagttgattatggagaaaaa Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T MNV (GV) VPg 102-124 GST-MNV VPg 102-124 R113A R tttttctccataatcaacttgcgcgtcatcgtctgcccaacttgg Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-HuASt4 VPg 75-93 GST-HuAst4 Nterm F GATCTGGTTCCGCGTGGATCCGACGACGACGGGTGGGGTGTTGTAGGAGACGATGTA Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-HuASt4 VPg 75-93 GST-HuAst4 N-Term R TACATCGTCTCCTACAACACCCCACCCGTCGTCGTCGGATCCACGCGGAACCAGATC Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-HuASt4 VPg 75-93 GST-HuAst4 PSWAD F CCGCGTGGATCCGGTGTTGTAGGACCAAGTTGGGCAGACGACGATGTAGAATTTGAT Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T GST-HuASt4 VPg 75-93 GST-HuAst4 PSWAD R ATCAAATTCTACATCGTCGTCTGCCCAACTTGGTCCTACAACACCGGATCCACGCGG Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T_mod eIF4GI HEAT-1 (751-1010) GST-4GI HEAT-1 C-term 6xhis  F gaccagatccataaggaggctcatcaccatcaccatcactgagaattcatcgtgactgac Plasmids(for(protein(expression(in!E.!coli.(
pGEX2T_mod eIF4GI HEAT-1 (751-1010) GST-4GI HEAT-1 C-term 6xhis  R gtcagtcacgatgaattctcagtgatggtgatggtgatgagcctccttatggatctggtc Plasmids(for(protein(expression(in!E.!coli.(
Oligonucleotides - Quantitive PCR
Target Sequence 5′ - 3′ 
MNV71(cDNA F CAAACATCTTTCCCTTGTTC Measurement(of(viral(replication
MNV71(cDNA R TGGACAACGTGGTGAAGGAT Measurement(of(viral(replication
Supplementary,Table,3,0,Expression,Details
Numbering NCBI accession Vector E. coli cell type [IPTG] mM Expression temp (° C) RPM Expression time (hours) Other details
MNV VPg  WT and mutants 1-124 DQ285629.1 pETM-11 BL21-Rosetta(DE3) 1 20 220 4 Chilled on ice for 5 min before induction
FCV VPg 1-111 AY560114.1 pETM-11 BL21-Rosetta(DE3) 1 20 220 4 Chilled on ice for 5 min before induction
GST-MNV VPg C-term WT and mutants 102-124 DQ285629.1 pGEX-2T BL21-CodonPlus(DE3) RIPL 1 37 220 4
GST-LDV VPg C-term 111-133 P54634.1 pGEX-2T BL21-CodonPlus(DE3) RIPL 1 37 220 4
GST-NV VPg C-term 116-138 AAC64602.1 pGEX-2T BL21-CodonPlus(DE3) RIPL 1 37 220 4
GST-BoNV VPg C-term 93-115 AC304905.1 pGEX-2T BL21-CodonPlus(DE3) RIPL 1 37 220 4
GST-FCV VPg C-term 87-111 AAT66080.1 pGEX-2T BL21-CodonPlus(DE3) RIPL 1 37 220 4
GST-HuASt4 VPg  C-term WT and mutants 73-91 Q3ZN06.2 pGEX-2T BL21-CodonPlus(DE3) RIPL 1 37 220 4
GFP-MNV VPg WT and F123A 1-124 DQ285629.1 pETM-11-mod1* BL21-CodonPlus(DE3) RIPL 1 20 220 4 Chilled on ice for 5 min before induction
GFP-VPg|NS6 fusion C139A 1-307 DQ285629.1 pETM-11-mod1* BL21-CodonPlus(DE3) RIPL 1 20 220 4 Chilled on ice for 5 min before induction
eIF4GII HEAT-1 745-1003 NP_003751.2 pMALX(E) BL21-CodonPlus(DE3) RIPL 1 37 220 3
eIF4GII HEAT-1 745-1003 NP_003751.2 pETM-11-mod1* BL21-CodonPlus(DE3) RIPL 1 30 220 4
eIF4GI HEAT-1 751-1010 AAM69365.1 pETM-11-mod2** BL21-CodonPlus(DE3) RIPL 1 20 220 7
eIF4GI HEAT-1 trunacted WT and mutants 748-993 AAM69365.1 pETM-11-mod1* BL21-CodonPlus(DE3) RIPL 1 30 220 4
GST-eIF4GI HEAT-1 751-1010 AAM69365.1 pGEX-2T_mod1‡ BL21-Rosetta(DE3) 1 37 220 4
GST-eIF4GII HEAT-1 745-1003 NP_003751.2 pGEX-2T_mod1‡ BL21-Rosetta(DE3) 1 37 220 4
GST-eIF4GI 4GM 652-1132 AAM69365.1 pGEX-2T_mod1‡ BL21-CodonPlus(DE3) RIPL 1 30 220 4
GST-eIF4GI 652-751-C-term_his 652-750 AAM69365.1 pGEX-2T_mod1‡ BL21-CodonPlus(DE3) RIPL 1 30 220 4
GST-eIF4GI 1011-1132-C-term_his 1011-1132 AAM69365.1 pGEX-2T_mod1‡ BL21-CodonPlus(DE3) RIPL 1 30 220 4 Chilled on ice for 5 min before induction
GST-eIF4GI HEAT-1-C-term_his 751-1010 AAM69365.1 pGEX-2T_mod1‡ BL21-CodonPlus(DE3) RIPL 1 30 220 4
DAP5 HEAT-1 61-323 NP_001036024.3 pETM-11-mod1* BL21-CodonPlus(DE3) RIPL 1 30 220 4
GST-DAP5 HEAT-1 61-323 NP_001036024.3 pGEX-2T_mod1‡ BL21-CodonPlus(DE3) RIPL 1 30 220 4
eIf4A 1-406 NP_001407 pET15B_mod‡‡ BL21-CodonPlus(DE3) RIPL 1 30 220 4.5
GST pGEX-2T BL21-Rosetta(DE3) 1 37 220 4
* BamHI engineered to replace NcoI site at the 5' linker site of pETM-11
** Thrombin engineered into replace the TEV Nia site in Mod_pETM-11_1
‡ TEV Nia site engineered to replace the thrombin site of pGEX-2T
‡‡ Described in Pestova et al., 1996, and Pisarev et al., 2007.
Supplementary,Table,4,0,NMR,Solutions
Component Final,concentration 1000x vitimin solution w/v (g/L) 1000x micronutrient solution M
Na2PO4 50 mM Choline chloride 0.4 (NH4)6Mo7O24·4H2O 3x10
-6 M
KH2PO4 25 mM Folic acid 0.5 H3BO3 4x10
-4 M
NaCl 20 mM Pantothenic acid 0.5 CoCl2 3x10
-5 M
15NH4Cl 36 mM Nicotinamide 0.5 CuSO4 1x10
-5 M
Glucose 54 mM Myo-Inositol 1 MnCl2 8x10
-5 M
MgSO4 2 mM Pyridoxal HCl 0.5 ZnSO4 1x10
-5 M
CaCl2 500 µM Thiamine HCl 0.5
FeSO4 10 µM Riboflavin 0.05
Vitamins 1x (See 1000x solution for details) Biotin 1
Micronutrients 1x (See 1000x solution for details)
Supplementary,Table,5,0,Buffers
Figure,1B,,GST,tagged,(4GI,4GM)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer Conc,(mM)
NaCl 200 NaCl 200 NaCl 200
Tris+pH+7.6 50 Tris+pH+7.6 50 Tris+pH+7.6 50
22mercaptoethanol 2 22mercaptoethanol 2
Figure,1B,GST,tagged,(GST,and,4GI,HEAT01)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM)
NaCl 200 NaCl 200
Tris+pH+7.6 50 Tris+pH+7.6 50
22mercaptoethanol 2
Figure,1B,His,tagged,(MNV,VPg,10124)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM)
NaCl 300 NaCl 300
Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 50 Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 50
DTT 1 DTT 1
Figure,1B,GST,and,his,tagged,(4GM0N,,HEAT01,and,4GM0C),4GI
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM)
NaCl 150 NaCl 150
Tris+pH+7.6 50 MES+pH+6.5 25
22mercaptoethanol 2 22mercaptoethanol 2
Figure,1C,GST,tagged,(GST),, See,Figure,1B
Figure,1C,GST,tagged,(4GM), See,Figure,1B
Figure,1C,His,tagged,VPg,proteins
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer Conc,(mM)
NaCl 300 NaCl 300 NaCl 300
Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 50 Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 50 Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 50
DTT 1 DTT 1 DTT 1
Figure,2A,untagged,MNV,VPg,1085 Same,as,His,tagged,VPg,proteins,in,Figure,1C
Figure,2A,GST,and,His,tagged,eIF4GI,HEAT01 See,Figure,1B
Figure,2A,untagged,MNV,VPg,10124
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer Conc,(mM)
NaCl 300.0 NaCl 150 NaCl 150
Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 50.0 MES+pH+6.5 25 MES+pH+6.5 25
DTT 1.0 22mercaptoethanol 2 DTT 3
Figure,2C,GST,tagged,(GST,4GI,and,4GII,HEAT01,domains) ,See,Figure,1B
Figure,2C,his,tagged,(MNV,VPg,10124),0,See,suppllimentry,methods,for,extended,notes
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM)
NaCl 300 NaCl 300
Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 50 Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 50
22mercaptoethanol 2 22mercaptoethanol 2
Figure,2D,his0tagged,(His0GFP0VPg,fusions)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer Conc,(mM)
NaCl 300 NaCl 150 NaCl 300
Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 50 MES+pH+6.5 25 Tris+pH+8 50
DTT 1 22mercaptoethanol 2 22mercaptoethanol 2
Figure,2D,his0tagged,(His0GFP0VPg|NS6,C139A,fusion)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer Conc,(mM)
NaCl 300 NaCl 300 NaCl 300
Tris+pH+8 50 Tris+pH+8 50 Tris+pH+8 50
22mercaptoethanol 2 22mercaptoethanol 2 22mercaptoethanol 2
Figure,2D,,untagged,originally,his,tagged,(eIF4GII,HEAT01)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer Conc,(mM)
NaCl 200 NaCl 200 NaCl 150
MES+pH+6.5 25 MES+pH+6.5 25 MES+pH+6.5 25
22mercaptoethanol 2 22mercaptoethanol 2 22mercaptoethanol 2
Figure,3A,untagged,0,originally,his,tagged,(eIF4GI,HEAT01)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer Conc,(mM)
NaCl 150 NaCl 150 NaCl 150
Tris+pH+8 50 Tris+pH+8 25 MES+pH+6.5 25
22mercaptoethanol 2 22mercaptoethanol 2 DTT 3
Figure,3A,untagged,0,originally,his,tagged,(eIF4GII,HEAT01)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer Conc,(mM)
NaCl 200 NaCl 150 NaCl 150
MES+pH+6.5 25 MES+pH+6.5 25 MES+pH+6.5 25
22mercaptoethanol 2 22mercaptoethanol 2 DTT 3
Figure,3B,untagged,0,originally,his,tagged,(DAP5,HEAT01)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer Conc,(mM)
NaCl 150 NaCl 150 NaCl 150
MES+pH+6.5 25 MES+pH+6.5 25 MES+pH+6.5 25
22mercaptoethanol 2 22mercaptoethanol 2 22mercaptoethanol 2
Figure,3C,untagged,0,originally,his,tagged,(eIF4GII,HEAT01)
NaCl 150 NaCl 150 NaCl 150
MES+pH+6.5 25 MES+pH+6.5 25 MES+pH+6.5 25
22mercaptoethanol 2 22mercaptoethanol 2 22mercaptoethanol 2
Figure,3C,untagged,MNV,VPg,10124 See,Figure,2A
Figure,S2,MBP,tagged,(eIF4GII,HEAT01)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer Conc,(mM)
NaCl 150 NaCl 150 NaCl 150
Tris+pH+8 20 MES+pH+6.5 25 MES+pH+6.5 25
22mercaptoethanol 1 DTT 0.75 DTT 3
Figure,4,his,tagged,(eIF4GI,HEAT01)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM)
NaCl 300 NaCl 200
Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 50 MES+pH+6.5 25
DTT 1 22mercaptoethanol 2
CaCl2 2
Figure,4,GST,tagged,(GST0VPg,C0terminii,fusions)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM)
NaCl 200 NaCl 200
Tris+pH+7.6 50 MES+pH+6.5 25
22mercaptoethanol 2
Figure,5A,untagged,originally,his,tagged,(eIF4GI,HEAT01)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer Conc,(mM)
NaCl 150 NaCl 150 NaCl 150
Tris+pH+8 50 Tris+pH+8 25 MES+pH+6.5 50
22mercaptoethanol 2 22mercaptoethanol 2 22mercaptoethanol 5
Figure,5D,untagged,originally,his,tagged,(eIF4GI,HEAT01)
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer,(pH,7.4) Conc,(mM)
NaCl 150 NaCl 150 NaCl 136.9
Tris+pH+8 50 Tris+pH+8 25 KCl 2.7
22mercaptoethanol 2 22mercaptoethanol 2 Na2HPO4 10.1
KH2PO4 1.8
TCEP.HCl 1
Figure,5D,,his,tagged,(MNV,VPg,10124)
Purification,Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer Conc,(mM)
NaCl 300 NaCl 300 NaCl 150
Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 50 Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 50 MES+pH+6.5 25
DTT 1 DTT 1 22mercaptoethanol 2
Figure,6,untagged,originally,his,tagged,eIF4A,10406
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM)
NaCl 200 NaCl 200
Tris+pH+7.6 50 Tris+pH+7.6 50
22mercaptoethanol 2 22mercaptoethanol 2
CaCl2 2
Figure,6,untagged,originally,his,tagged,MNV,VPg
Purification,buffer Conc,(mM) Dialysis,buffer Conc,(mM) SEC,buffer Conc,(mM)
NaCl 300 NaCl 300 NaCl 300
Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 50 Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 25 Na.PO4+pH+6.5+(15.8+mM+Na2HPO4+,+34.2+mM+NaH2PO4)++++++++++++++++++++++++++++++++ 25
DTT 3 DTT 3 DTT 2
Figure,6,his,tagged,eIF4GI,HEAT01,,(See,Figure,3A)
Figure,7,GST,tagged,(GST0VPg,C0terminii,fusions) See,Figure,4
